iaslc 2015 annual report

IASLCI N T E R N A T I O N A L A S S O C I A T I O N F O R T H E S T U D Y O F L U N G C A N C E R

2015 Annual Report

Alex A. Adjei, MD, PhD, FACP, Editor-in-ChiefVolume 11, Number 2, February 2016

Journal ofThoracic Oncology

Of cial Publication of the International Association for the Study of Lung Cancer www.jto.org

JTHO_v11_i2_COVER.indd 1 24-12-2015 16:35:07

WELCOME TO THE IASLC

16TH WORLD CONFERENCE

ON LUNG CANCER

Conference Program Book

FOLLOW US ON TWITTER @IASLC #WCLC2015

FOLLOW US ON FACEBOOK

WWW.IASLC.ORG

BECOME A MEMBER OF IASLC VISIT WWW.IASLC.ORG

3ANNUAL REPORT 2015

Table of Contents

Introduction 4

OrganizationStructure 5

Membership 10

Communications 12

Fellowships 14

EducationalActivities 16

Publications 19

Meetings 26

Awards 34

SponsorsandAdvocacyPartners 38

StrategicPlan 39

IASLCFoundation 44

FuturePerspective 46

IASLCinPublications 47

4IASLC

Thanks to the hard work of our dedicated staff and the worldwide support of our members, 2015 was a banner year for the IASLC and for progress in lung cancer treatment.

Lung cancer remains a major global health problem. Worldwide, more than 1.8 million individuals are diagnosed with the disease, which causes 1.6 million deaths, every year. However, as we saw in 2015, major scientific advancements offer new hope to many lung cancer patients.

While the survival rate for many with lung cancer remains low, new targeted therapies and immunotherapies have the ability to change those statistics. Just this year, two immunotherapy drugs were approved by the U.S. FDA for lung cancer therapy. Immunotherapy continues to demonstrate very encouraging results, particularly in patients who have failed first-line therapy. Lung cancer screening with low-dose computed tomography (CT) has been demonstrated to reduce the lung cancer mortality by 20 percent in high-risk individuals. New advancements in molecular biology provide knowledge of heterogeneity of lung cancer, leading to personalized therapy. As we identify more subgroups it will have a dramatic effect of creating even more specific targeted therapies. All this has transformed lung cancer research and treatment into a role model for modern cancer treatments.

Among the major highlights from 2015 are the completion of two of IASLC’s global initiatives: The 8th Edition of the Tumor, Node and Metastasis (TNM) Classification of Lung Cancer, this time including the thymus and esophagus, and the 2015 WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (Fourth edition). Congratulations to all those involved in these very significant projects.

In 2015, we smoothly transitioned our journal, Journal of Thoracic Oncology, to a new publisher, Elsevier. The first issue published by Elsevier debuted in January 2016.

Never in our history has the IASLC enjoyed the outreach we had in 2015; our accomplishments vaulted our membership to a record high of more than 5,000 members in more than 100 countries. In addition to our successful webinars in both the U.S. and Europe, the IASLC School of Thoracic Oncology arranged several Live Learning programs, designed for fellows and junior faculty members in particular.

We enjoyed incredible success in all our 2015 meetings, notably the World Conference on Lung Cancer (WCLC) in Denver which gathered over 6,000 participants from nearly 100 countries and showcased many new advances in lung cancer science. We also launched more focused, smaller meetings, such as the Small Cell Lung Cancer meeting

and the consensus meeting on Management of EGFR Mutant NSCLC.

The new IASLC Mentorship Award provided experienced IASLC mentors to 13 fellows during the WCLC. After the conference, they spent one week at a U.S.-based academic institution.

Because of the rapid pace of the progress in lung cancer, our molecular guidelines committee is already working to revise the IASLC/CAP/AMP Guidelines for Molecular Testing in NSCLC, new revisions of the ALK Atlas, which will now include ROS1, and development of a PD-L1 Atlas, which should help physicians and patients select the most appropriate immunotherapy treatment. While immunotherapy emerged as a promising treatment for lung cancer, the predictive assays related to this raised issues which the IASLC, together with other organizations, took the lead to solve through a coordinated Blueprint Project in collaboration with industry partners.

A core value for the IASLC is to develop and educate the next generation of investigators. Our generous members and outside donors gave strong support to the IASLC Foundation in 2015 and we look forward to expanding the Foundation and its support for young investigators to continue preventive and therapeutic scientific developments worldwide in the years to come.

We already have our sights set high for 2016. We will expand on our 2015 accomplishments with an additional emphasis in Asia and we will launch a new magazine that will include commentaries on all aspects of lung cancer science and management. The IASLC is also expanding our staff and office space to meet the growing demand for our support.

At the conclusion of this successful year, we thank our members and our staff for their commitment to the IASLC and to our mission to reduce lung cancer mortality all over the world.

Introduction

Fred R. Hirsch, MD, PhD David P. Carbone, MD, PhD ChiefExecutiveOfficer President

5ANNUAL REPORT 2015

Organiza�on

President

USA2015-2017

President Elect

Italy2015-2017

Past President Tony MokHong Kong2015-2017

Past President

United Kingdom2013-2015

Chief

USA

Treasurer

USA

Alex AdjeiUSA

2011-2015USA

2011-2015Germany

2011-2015

Tetsuya MitsudomiJapan

2011-2015Japan

2011-2015

Silvia NovelloItaly

2011-2015

Thailand2011-2015

USA2013-2017

USA2013-2017

United Kingdom2013-2017

iFrance

2013-2017Japan

2013-2017

Switzerland2013-2017

China2013-2017

Australia

2015-2019

USA

2015-2019Japan

2015-2019Austria

2015-2019

Germany2015-2019

Japan

2015-2019USA

2015-2019USA

2015-2019

2013-2017

6IASLC

Position NameChiefExecutiveOfficer FredR.Hirsch

DirectorofEducation,CorporateRelationsandGovernance PiaHirsch

DirectorofFinance JohnSkadow

DirectorofMembership KristinRicheimer

DirectorofCommunications JeffWolf

ScientificProjectsManager MurryWynes

CMEEducationCoordinator PaulSilvey

JTO Managing Editor MaryTodd

ProjectsSpecialist BeckyBunn

DataandTechnicalAnalyst MichelleGarcia

ScientificProjectsSpecialist JacintaWiens

AsianOffice VengieLau

IASLC Committees (2015-2016)

IASLC Staff

Committee Chair Past-Chair 2015 AccomplishmentsAwards DavidCarbone TonyMok Selectedthe2015IASLCDistinguishedAwardwinners.

Bylaws ToBeAnnounced

CareerDevelopmentandFellowship

BenSolomon MartinEdelman/BenjaminBesse

TheCommitteereviewedandrankedseveralFellowshipapplications during2015,evaluatingyoungresearchersinordertorewardscientificexcellenceandtoencourageinnovativeresearchinlungcancerpreventionandtranslationalmedicineworldwide.InthecomingyearmoreawardswillbereviewedandselectedandtheCommitteewilldevelopCareerDevelopmentinitiativesforIASLC.

Communications RossSoo AnneTsao TheCommunicationsCommitteeplayedakeyroleinleadingcommunicationseffortsforthe16thWorldConferenceonLungCancerinDenver,helpedguidepromotionaleffortsforarticlesintheJournal of Thoracic Oncology(JTO),improvedthedeliveryofIASLC’smonthlynewsletterandprovidededitorialassistanceforthedailynewspaperattheWCLC.

Education FedericoCappuzzo SureshRamalingam TheCommitteedevelopedmultidisciplinarycurriculumforfellowsandyounginvestigatorswhichispostedontheIASLCwebsite.TheCommitteealsoevaluatedrequestsforIASLCendorsedmeetingsanddevelopedLiveLearningProgramswhichwereinitiatedin2015andwillcontinueinthefuture.

AdvancedRadiationTherapy(ART)

LaurieGaspar FrancoiseMornex

HakChoy ThisSubcommitteeoftheEducationCommitteecontinuedthegrowthandexpandedtheIASLCwebinarprogram,whichstartedin2012,worldwide.

ContinuingMedicalEducation(CME)

RamaswamyGovindan

ThisSubcommitteeoftheEducationCommitteeensuresadherencetoCMErules,identifyingambassadorstomonitorallIASLCmeetings.

Ethics ThierryMarieJahan EduardoRichardet/ThierryMarieJahan

In2015,theEthicsCommitteeworkedtohelpstreamlinetheConflict OfInterestsubmissionprocessfortheBoard,CommitteeMembersandallIASLCvolunteers.TheCommitteeseekstobeproactiveon emergingissuesandbestpracticesaroundtheworld.

Finance DavidGandara FredR.Hirsch EnsuredthattheIASLCmaderesponsibleandsoundfinancialdecisions.

7ANNUAL REPORT 2015

Membership LuisRaez SurishSenan TheMembershipCommitteeoversawanotherrecordyearofIASLCmembershipin2015.VolunteersfromtheMembershipCommitteeservedasambassadorsattheIASLCExhibitBoothatvariousmeetingsandalsoworkedtointroducenewpartnersocietiestoIASLCforjointmembershipoffers.TheCommitteeexpandedtheIASLCfreeFellowMembershipprogramtoallowgroupregistrationandwillcontinuetoencourageglobalgrowthinallregionsandsub-specialties,particularlythosecurrentlyunder-representedinIASLCMembership,suchasRadiationOncology,Pulmonology,Pathology,andNursingandAlliedHealthProfessions.

Nominating JoanSchiller KathyAlbain Selectedtheslateofpotential2015-2017BoardofDirectorscandidates.

Nurses&AlliedHealthProfessionals

JohnWhite PatriciaHollen TheCommitteepromotedaResourceCenterwhichreceivednearly10percentofallIASLC.orgwebsitetrafficMarch-December2015,developedanagendaforN&AHPsessionscompletedforthe2015WCLCConferenceandwroteamanuscript,“Supportivecareinlungcancer:Milestonesoverthepast40years,”recentlypublishedintheJTO.

Pathology YasushiYatabe AndrewNicholson TogetherwiththeWHO,thePathologyCommitteedevelopedthenewWHOClassificationofTumoursoftheLung,Pleura,ThymusandHeart.

PatientAdvocacy GlendaColburn GlendaColburn TheCommitteelaunchedseveralnewinitiatives,mostlyfocusedonWCLCin2015,includingaPatientAdvocacyTrackatWCLC,uniqueregistrationratesforadvocates,survivorsandadvocacyorganizations,creatingpatientlocalliaisonsandadvocacytravelgrants.

Prevention,Screening&Early

Detection

ToBeAnnounced NirPeled TheCommitteeheldanall-daysoldoutworkshoponplanningfortheimplementationoflungcancerCTscreeninginternationallyatWCLC2015andhadacomprehensiveprevention,screening,andearlydetectionprogrambecauseoftheworkbythecommitteeanditsmembers.Committeememberswroteadocumentonestablishingalungcancerscreeningclinic,withtheaimofhelpingcentersthroughastandardizedapproach.TheCommitteeisalsoworkingondocumentsandtoolsonthewebsiteforriskassessment,nodulemanagement,andinformationonwhatdatashouldbecollected.Movingforward,theCommitteewilladdressgroundglassopacitymanagementandthecreationofanimageatlasinordertostandardizeandsupportbetterclinicaldecisions.

Publications DavidSpigel HarveyPass ThePublicationsCommitteeassistedinthedecisiontomovetoanewpublisherfortheJournalofThoracicOncology,takingpartinthedecisiontomovethejournaltoElsevier;openeddiscussionswithElsevieraboutaneweditionoftheIASLCtextbook;helpedtodeveloparticlesdetailingtheprogressinlungcancerin2015fortheJTO; andlooksforwardtohelpingwiththelaunchofthe newmagazine,IASLCLungCancerNews,in2016.

Staging RamonRami-Porta PeterGoldstraw TheStagingCommitteedevelopedthe8thEditionoftheStagingofLungCancer.SeveralpublicationshavealreadybeenpublishedintheJTO.

TobaccoControl/SmokingCessation

MichaelCummings CarolynDresler TheCommitteeproducedamonthlyJTOsectiononglobaltobaccocontrolandsmokingcessation.TheWCLC2015hadthemostcomprehensivetobaccocontrolandsmokingcessationprogramforanyworldconference,includingthelaunchofaCommittee-updatedIASLCStatementonTobaccoControlandSmokingCessation.TheIASLC,attherecommendationoftheCommitteeandinassociationwithdozensofothersocieties,signedontomultiplepolicylettersrelatedtotobaccocontrolin2015.EducationalTobaccoExhibitsproducedbytheMedicalUniversityofSouthCarolinaandtheRoswellParkCancerInstituteweredisplayedatmultipleIASLCmeetings.TheCommitteesponsoredtwowebinarsin2015.AbrochureonsmokingcessationandtobaccocontrolforphysicianswasstartedbytheCommitteeandwillbelaunchedin2016.

AsiaPacific LungCancer

SumitraThongprasert

PlannedtheAPLCCmeetingsinSoutheastAsia.

8IASLC

Task Force Chair(s) Past ChairIndustry GiorgioScagliotti

PaulA.Bunn,Jr.RolfStahel

QualityandValue RonanKelly

Regent Area Regent Name Specialty & LocationAustralasia NickPavlakis MedicalOncology,SydneyBrasil MauroZamboni ThoracicSurgery,RiodeJaneiroCanada GailDarling(Chair2012-2015) ThoracicSurgery,TorontoCentralAmericaandMexico OscarArrieta MedicalOncology,MexicoCityCentralEurope GyulaOstoros MedicalOncology,BudapestChina Yi-LongWu ThoracicSurgery,GuangzhouEurope(1) RudolphHuber MedicalOncology,MunichEurope(2) LucioCrino MedicalOncology,PerugiaEurope(3) PauldeLeyn ThoracicSurgery,LeuvenEurope(4) CecilelePechoux RadiationOncology,ParisGreece IoannisGkiozos Pulmonology,AthensGulfStatesandArabia KhaledAl-Kattan ThoracicSurgery,RiyadhIndianSub-Continent DigembarBehera Pulmonology,ChandigarhJapan(1) ShujiSakai ThoracicSurgery,TokyoJapan(2) IchiroYoshino ThoracicSurgery,ChibaKorea YoungTaeKim ThoracicSurgery,SeoulNorthAmerica HeatherWakelee MedicalOncology,StanfordNorthAmerica CharlesPowell Pulmonology,Mt.SinaiNorthAmerica BrianLally RadiationOncology,MiamiNorthAmerica GerardA.Silvestri Pulmonology,CharlestonRussia ValeriyBreder MedicalOncology,MoscowSouth-EastAsia IbrahimWahid RadiationOncology,KualaLumpurSouthernAfrica TonyLinegar ThoracicSurgery,CapeTownSpanishSouthAmerica EduardoRichardet MedicalOncology,CordobaTaiwan JamesChih-HsinYang MedicalOncology,TaiwanTurkey DenizYalman RadiationOncology,IzmirUKandIreland RichardBooton Pulmonology,Manchester

IASLC Council of Regents

IASLC Task Forces

9ANNUAL REPORT 2015

Organization OverviewMembers–ThosebelongingtotheIASLCcomefromawiderangeoffieldsandbackgrounds.Ourorganizationbringstogetherclinicalpractitioners,scientists,patientadvocates,nursesandindustryexecutivesunitedinthegoalofprevention,screening,imaging,diagnosisandtreatmentofthoracicmalignancies.Werelyontheexpertiseofourmembersasweworktofindnewwaystocollaborateandsharethemosttimelyandrelevantscientificandclinicalinformationaroundtheworld.LeveragingtheseresourcespositionstheIASLCasthepremierglobalsourceofinformationonthoracicmalignancies.MembersdevotetheirtimetoleadingIASLCsponsoredmeetingsandconferences,takeactiverolesinvariouscommittees,providepresentationsoncutting-edgebasic,translational,andclinicalscienceandengageinrobustinteractionstofurthertheIASLCmission.

Board of Directors–TheIASLCBoardofDirectorsismultidisciplinaryandeachmemberbringsanabundanceofclinicalandscientificexpertise,alongwithabroadbaseofexperiencewithothersocietiesandfamiliaritywithinstitutionalleadership.IASLCboardmemberspromoteongoinggrowthinprogramsandnewinitiativesthroughtheirstrategicguidanceaswellastheiroperationalandfinancialoversight.

Headquarters Staff–UndertheleadershipoftheCEO,thestaffimplementsawiderangeofeducation,membership,communication,outreach,fundraisingandscientificprogramsfortheorganization.Fromfacilitatingmanyworldwideconferencestoproducingwebinars,publishingbooksanddigitalapplications,collaboratingwithcommitteesandmembers,disseminatingthelatestscientificadvancesandworkingwiththemediaglobally,thestaffdistributesthebestandlatestinformationtoourmembersandthepublicacrosstheglobe.Thestaffworksdiligentlytokeepcontactinformationup-to-dateandisaccountableforthemanagementofIASLCfinances,includingobtainingsponsorshipsforvariousactivitiesandevents.Thestaffsupports,givesexpertadviceandhelpsimplementdecisionsmadebyIASLCcommitteesandtheBoard ofDirectors.

10IASLC

IASLC Membership Reaches Record High of 5,000 Members IASLCstaffsetandattainedalandmarkgoalof5,000activemembersin2015,anincreaseof47percentcomparedwith2014,byactivelyengagingwithcurrentmembers,creatingnewandinnovativewaysofreachingnewpotentialmembers,andenrollingarecordofmorethan1,500newmembersthisyear.

Severalkeyinitiativesshouldbecreditedforthisgrowth:

» IASLC Membership Booth Promotions and Partner Society Offers: Launchedasapilotprogramin2015,new membersfromtheseinitiativesamounttoanestimated 10percentoftotalmembers.WithIASLC’sMembershipBoothpresenceatsocietiesforThoracicSurgery,

PulmonologyandMedicalOncologyinEuropeandNorthAmerica,wecontinuetoincreaseIASLCexposureinunder-representedspecialtiesandregionsoftheworld.

» WCLC 2015 Registration:WhilemembershiphistoricallyincreasesduringWCLCyears,IASLCimprovedthedatasharingandregistrationprocessthisyeartocapturemembershipasindividualscompletedWCLCregistration.Inaddition,manynewmemberstookadvantageofthemulti-yeardiscountofferattheWCLCinDenver,Colorado.

» Retention & Recovery:IASLCretainedandrecovered88percentofformermembersandlapsedmembers,whichisanincreaseoverpastyears’retentionrate.

» Early-Career Members: IncreasedpromotionofthefreeFellowmembership,availabletoFellows,ResidentsandTraineesinalldisciplinesledtogrowthinthismembercategory.Weencourageallmembersto“Invite-a-Fellow”orutilizetheGroupFellowRegistrationtomakesureearlycareerphysiciansandinvestigatorscanbenefitfromthisincrediblevalue.

» Improved Technology: Improvementstothememberdatabaseandemailmarketingsoftwareprovidedbettermemberdataandallowedmorefrequentnoticestobedistributedtolapsedmembers.

Membership

2015 Members by Specialty 2015 Members by Region

Cancer Research/ Basic Sciences, 6%

Radiation Oncology/ Diagnostic Radiology,

9%

Pathology, 5% Nursing, 4%

Other, 11%

PulmonaryMedicine,

14%

Medical Oncology,32% Europe,

23%

North America, 35%

Asia, 28%

Rest of the World, 6%

Latin America, 6%

ThoracicSurgery,

20%

11ANNUAL REPORT 2015

Attracting Members from the Entire Multidisciplinary TeamIASLCestablishedagoalofeducatingtheentireteamofprovidersforlungcancerpatients.Tofurtherthatgoal,IASLCupdateditsmembercommunicationstoincludelanguagetomakeitclearthatIASLCmembershipisvaluabletoanyonewhoisinvolvedinlungcanceraroundtheworld.IASLCactivelyseekstoincreaseitsmembershipamong:

• Pathologists• Diagnosticradiologists• Nursesandalliedhealthprofessionals• Communitypractitioners• Industryprofessionals

TheseriesofAdvancedRadiationTechnology(ART)Webinarsprovidedauniquevehicletoattractnewmembersinradiationoncology,andourpartnershipswithsubspecialtysocietiesaroundtheworldincreasethevisibilityandmembershipofIASLC.

Member Engagement and BenefitsIn2015,theIASLCintroducedthemembershipcardandsentonetoallactivemembers.ManymembersbroughttheircardstothemembershipboothtogetanIASLCmemberpinandinvitedcolleaguestojoin.Inaddition,werevivedtheprintedMemberDirectoryin2015andallmemberscouldchoosetoreceiveoneinthemail.Forthefirsttime,welaunchedtheIASLCVirtualLibrarywitheducationalcontentfromWCLC2015and2013,makingitavailabletomembersontheIASLCwebsitethroughtheirIASLCmembershiplogin.MemberswhodidnotattendtheWCLCcouldalsopurchaseaccesstotheWCLC2015VirtualMeetingfor$99USD.Additionally,allactivememberscanaccesstheWCLC2013contentfreeofcharge.Membersandmeetingattendeeswerealsoeagertopickupthe8thEditionTNMStagingCardProposalsatmanymeetingsaroundtheworld.

The Years Ahead - Collaboration Welcome!TheIASLCencouragesmembers,partnersocietiesandindustrypartnerstopursuebeneficialcollaborations.Ahighpriorityforearly2016istheofficiallaunchoftheCorporateMembershipProgram.TheIASLCMembershipDepartmentandMembershipCommitteeremaincommittedtocontinuedaggressivegrowth,particularlyinunder-representedspecialtiesandregionsoftheworld.Wewelcomemembersuggestionsandideasforcollaborations,whichcanbesubmittedanytimetotheIASLCMembershipCommittee,MembershipDirectorortheIASLCRegentinyourlocation.Wethankyouforyourcommitmenttoconqueringthoraciccancersworldwide!

New members from the following societies can receive additional discounts!

12IASLC

In2015,theIASLC’scommunicationseffortsachievedgreaterreachthaneverbefore,garneringmediaattentionandheadlinestoriesaroundtheworld.Duringtheyear,wepublishedmorethan60newsreleases,focusingonscientificadvancements,lungcancerawarenessandthe2015WCLCtopabstractsandawards.OurmediaeffortsincludedasignedlettertotheFDAcommissioneraddressingourcommunity’sconcernswithregulatoryactionthatpreventsresearchonvitalelectronicnicotinedeliverysystems(ENDS),andasignedlettertotheAmericanRedCrossaskingtheorganizationtostopacceptingmoneyfromthetobaccoindustry.IASLChasgreatplansforthefutureofourcommunications,includingbetterandmoretargetedcampaignsandwaystoensureourmembersstayup-to-dateonthelatestinourindustry.

WCLC 2015Duringthe16thWorldConferenceonLungCancerinDenver,IASLCpartneredwithapublicrelationsfirmtoexpandourreachexponentially.OurWCLC2015effortsincludedmorethantwodozenpressreleases,hundredsofemailstomediaprofessionals,fourpressconferences–oneforeachdayoftheWCLC,andmultipleinterviewswithnewsorganizations.

Theseeffortsresultedinmorethan1billionimpressionsandmorethan$400,000inAdValue,including

on-siteinterviewswithmultipleTVstationsandanarticleonthefrontpageofamajornewspaper.

Communications

Figures at-a-Glance


Lung Cancer Awareness MonthNovemberisrecognizedasLungCancerAwarenessMonthinmanycountries,andtheIASLConceagainparticipatedbyhostingevents,sharingsuccessesinlungcancertreatmentwiththemediaandcollaboratingwithinternationalmemberstoraiseawarenessoflungcancer.ThehighlightofoureffortsincludedaLungCancerAwarenessForumattheIASLCheadquarterswhereseverallungcancerpatientsjoinedwithlocaldoctorsandhealthprofessionalstosharetheirstoriesandtocollaboratebysharinginformation.Itwasanemotionalandrewardingexperienceforallandthestaffplanstoholdsimilareventsinthefuture.Additionally,weparticipatedinLungCancerSocialMedia’sTwitterchat,featuringanswersbyIASLCCEODr.FredR.Hirsch.WealsoannouncedthelaunchofanewinitiativebyIASLCtoimprovecommunicationsbetweenpatientsandhealthprofessionals.Lookformoreinformationonthisinitiativeinthecomingyear.OurmessagingthisNovemberfocusedonspreadingregionalfactsaboutlungcancerandondispellinglungcancermyths.TheIASLCalsosucceededingettingmediaoutletstodoseveralstoriestohelpraiselungcancerawarenessandheardfrommanyIASLCmembersfromacrosstheglobeaboutlocaleventstheyparticipatedintoraiseawareness.

NewsletterKeytokeepinginclosetouchwithourmembersisthedistributionofanewsletter,deliveredbyemailtoallmemberseachmonth.ThenewsletterincludesupdatesfromtheIASLCCEOandthePresident,

aswellasinformationonallupcomingevents,newinitiativesandabstractdeadlines.Fellowshipawards,keyJTOarticlesandadvocacyeffortscanalsobefoundfeaturedinthenewsletter.Toreportindetailonglobalactivities,theIASLCRegentsalsoofferinformationaboutinitiativesintheirregions.

Social MediaAsmoreandmoremembersandjournalistsexpandtheiruseofsocialmedia,theIASLCsharpensouruseoftechnologytoprovidequick,streamlinedinformation.IASLC’ssocialmedianumbersconsistentlyroseduring2015withtheIASLCFacebookpageseeingagrowthfromlessthan1,500likesandendingtheyearwithmorethan1,900.TheJTOFacebookpagealsoenjoyedyear-to-yeargrowth,startingwithmorethan2,300likesandendingwithmorethan2,500.TheIASLCTwitteraccountgainednearly700newfollowersduringtheyearandreachedahighpointduringSeptemberwith134,000Tweetimpressionsandnearly5,000profilevisits.

2015 Social Media Growth

3,000

2,000

1,000

0Twitter IASLC JTO

Facebook Facebook

DecemberJanuary

January December

14IASLC

Fellowship/Young Investigator Awards 2015 – 2016 FellowshipsremainakeypartoftheIASLCmission.In2015,IASLCcontinueditssupportforyoungresearchersinordertorewardscientificexcellenceandtoencourageinnovativeresearchinlungcancerpreventionaswellasinclinicalandtranslationalmedicineworldwide.TheIASLCacceptedapplicationsforFellowshipandYoungInvestigatorAwardsinJanuary,withcandidatesrepresentingNorthAmerica,AsiaandEuropeawardedresearchfundingaftercompetingwithaglobalpoolofapplicants.Globalsubmissionstoourfellowshipawardsincludedmanyexcellentcandidates,evaluatedbyaScientificReviewPanelfortheirmerit,innovationandpotentialimpactonthefuturemanagementandtreatmentoflungcancer.In2015,ajointcollaborationbetweenBoehringerIngelheimChinaandIASLCenabledafellowfromShanghai,ChinatocometotheUnitedStatestoperforma1-yearresearchproject.

Mark M. Awad Dana-FarberCancer

Institute,USA

Mentor & Institution: YoungInvestigatorDana-FarberCancerInstitute,USA

Project: DevelopmentofAssaystoDetectAntibodyandT-cellImmuneResponsestoAnaplasticLymphomaKinnsae(ALK)inNon-SmallCellLungCancer(NSCLC)Patients

Puey Ling ChiaTheAustinHospital,

Australia

Mentor & Institution: ThomasJohnTheAustinHospital,Australia

Project: Characterizationofthetumourmicroenvironmentinmesotheliomaforimmunoligicalandoncogenictargetedtherapies

Yayi He (BoehringerIngelheimChineseFellowship&IASLCFellow)

TongjiUniversity, Shanghai,China

Mentor & Institution: FredR.HirschUniversityofColorado,USA

Project: Studyonacquiredresistantmechanismstoafatinib(BIBW2992)inlungadenocarcinomawithHER2mutations

Jill E. LarsenQIMRBerghoferMedical

ResearchInstitute,Australia

Mentor & Institution: YoungInvestigatorQIMRBerghoferMedicalResearchInstitute,Australia

Project: Characterizationsof“cooperative”mutationsfortheirpotentialasacquiredvulnerabilitiesinKRAS-drivennon-smallcellcarcinoma

Colin LindsayInstitutGustave-Roussy,

France

Mentor & Institution: BenjaminBesseInstitutGustave-Roussy,France

Project: AssessingtheclinicalsignificanceofEPCAM-negativecirculatingtumourcellsinnon-smallcelllungcancer

Yoichiro MitsuishiDana-FarberCancer

Institute,USA

Mentor & Institution: MatthewMyersonDana-FarberCancerInstitute,USA

Project: ChemicalscreenforagentsthatdegradethelungcanceroncoproteinNrf2


Sara PilottoUniversityofVerona,Italy

Mentor & Institution: EmilioBriaUniversityofVerona,Italy

Project: Immunecheckpointregulatorsanddrivinggenemutationsasoutcomepredictorsforresectedsquamouscelllungcancer

Adrian G. SacherDana-FarberCancer

Institute,USA

Mentor & Institution: GeoffreyR.OxnardDana-FarberCancerInstitute,USA

Project: QuantitativePlasmaGenotypingasanIntegratedBiomarkerinAdvancedNSCLCTherapy

Kenichi SudaKinkiUniversity,Japan

Mentor & Institution: YoungInvestigatorUniversityofColorado,USA

Project: Foundationalinvestigationtooptimize3rdgenerationEGFR-TKItreatment–analyzingheterogeneityofresistanceandovercomingresistance

Piyada Sitthideatphaiboon(APLCC&IASLCFellow)ChulalongkornUniversity,

Thailand

Mentor & Institution: ViroteSriuranpongandTrairakPisitkun,MDAndersonCancerCenter,USA

Project: ProteomicsignatureforthedifferenceinchemotherapysensitivitybetweenmutantEGFRandwildtypeEGFRinnon-smallcelllungcancer

Silvestre VicentCenterforAppliedMedicalResearch(CIMA),Spain

Mentor & Institution: YoungInvestigatorCenterforAppliedMedicalResearch(CIMA),Spain

Project: DissectingthefunctionalroleofFos-likeantigen1(FOSL1)in KRAS-drivenLungCancer

IASLC would like to thank the following supporters of the IASLC Fellowship/Young Investigators Program:

»AstraZeneca »Boehringer Ingelheim »Bristol-Myers Squibb »Celgene »Daiichi Sankyo »Eli Lilly »Genentech »Pfizer »Prevent Cancer Foundation

16IASLC

Educational ActivitiesTobroadentheavailabilityofeducationalofferings,theIASLCexpandeditsnumberofContinuingMedicalEducation(CME)accreditedprogramsin2015,offering23webinarsondiversetopicsandorganizingmultipleLiveLearningevents.MembersaroundtheworldnowhavetheabilitytolearninpersonatmeetingsandLiveLearningevents,andtolearnfromtheirofficesthroughwebinars.TheIASLCGlobalCurricularFrameworkcontinuestoserveasaresourceforlifelonglearning.

Title: Best of 2014 Lung Cancer Research and High Priority NCI Lung Cancer Trials – CMESpeaker: RoyS.Herbst,MD,PhDModerator: RamaswamyGovindan,MD– ProgramChairDate: January20,2015

Title: Improving therapeutic outcomes for lung cancer patients: addressing the overwhelming evidence about tobacco use and cancer treatment. (Tobacco Control Committee Webinar)Speaker: GrahamWarren,MD,PhDModerator:CarolynDresler,MDDate: January21,2015

Title: Advances in NSCLC: Approaches to the Management of TKI ResistanceSpeakers: JonathanGoldman,MDand HeatheerWakelee,MDDate: February24,2015

Title: Chemotherapy Options for Metastatic Lung Cancer – CMESpeaker: MarkA.Socinski,MDModerator: RamaswamyGovindan,MD– ProgramChairDate: March4,2015

Title: E-Cigarettes: Friend or Foe? (Tobacco Control Committee)Speakers: MaciejGoniewicz,PhD BenToll,MDModerator:MatthewSteliga,MDDate: April1,2015

Title: New Therapies Are Coming for Malignant Pleural Mesothelioma – CMESpeaker: LeeM.Krug,MDModerator:RamaswamyGovindan,MD– ProgramChairDate: April2,2015

Title: Evolving Role of PD-1/PD-L1 Inhibitors in the Clinical Management of NSCLC – CMESpeaker: EdwardGaron,MDModerator:RamaswamyGovindan,MD– ProgramChairDate: June17,2015

Title: Current Role of Immunotherapy for Lung Cancer – CMESpeaker: ScottN.Gettinger,MDDate: June25,2015

Title: Advanced Radiation Technology Committee Live Webinar Series - Making Progress in Stage III NSCLC Management – CMESpeakers: DavidBall,MD MichaelMacManus,MDModerator: FrancoiseMornex,MD–ProgramChairDate: July9,2015

Title: Biomarkers and Personalized Medicine for Patients with Lung Cancer – CMESpeaker: Prof.KeithKerr,MDModerator:RamaswamyGovindan,MD– ProgramChairDate: July14,2015

IASLC Webinar Programs - 2015


Title: Combined Modality Treatment of Stage III NSCLC – CMESpeaker: SureshSenan,MDModerator:RamaswamyGovindan,MD– ProgramChairDate: July20,2015

Title: Advanced Radiation Technology Committee Live Webinar Series: Follow-up of patients after SABR (stereotactic ablative radiotherapy) for early stage NSCLC-A Primer for the Multidisciplinary Team – CMESpeakers: DavidPalma,MD SureshSenan,MDModerator: FrancoiseMornex,MD–ProgramChairDate: July21,2015

Title: EGFR TKIs: What is New? – CMESpeaker: LeciaSequist,MDModerator:RamaswamyGovindan,MD– ProgramChairDate: August26,2015

Title: Surgical Standards for NSCLC – CMESpeaker: WalterWeder,MDDate: September1,2015

Title: Advances in Radiation Therapy for Non-Small Cell Lung Cancer – CMEModerator:FrancoiseMornex,MD,PhDSpeakers: YasushiNagata,MD YongChanAhn,MDDate: September25,2015

Title: Ongoing Clinical Trials for Patients with Advanced Lung Cancer – CMEModerator:RamaswamyGovindan,MDSpeaker: DavidGandara,MDDate: October1,2015

Title: IASLC WHO Pathology Classification 2015 – CMESpeaker: AndrewNicholson,MDDate: October8,2015

Title: ASCO/IASLC 2015 Lung Cancer Updates for Radiation Oncologists – CME Moderator:LaurieGaspar,MDSpeakers: CliffordRobinson,MD SaimaWaqar,MDDate: October12,2015

Title: Staging of Lung Cancer – 2015 – CMESpeaker: RamonRami-Porta,MDDate: October14,2015

Title: WCLC 2015 UPDATE Moderator: RamaswamyGovindan,MDSpeaker: SureshRamalingam,MDDate: October21,2015

Title: Lung Cancer in Women – CMESpeaker: SilviaNovello,MDDate: November10,2015

Title: Challenging Cases in Early Stage Non-Small Cell Lung Cancer – CMEModerator:RamaswamyGovindan,MDSpeaker: HeatherWakelee,MDDate: November18,2015

Title: Challenging Cases in Advanced Stage Non-Small Cell Lung Cancer – CMEModerator: RamaswamyGovindan,MDSpeaker: AnneTsao,MDDate: December8,2015

18IASLC

Live LearningIASLChostedthreeLiveLearningeventsonmultidisciplinarytopics(pulmonology,medicaloncology,surgery,radiationoncologyandpathology)in2015.Theseworkshopswereopentophysiciansandalliedhealthprofessionalsinvolvedinthecareofpatientswithlungcancerandwereparticularlysuitedforearlycareerphysiciansandtrainees.ThesewereheldinNewYork,AtlantaandSanFranciscowithhugesuccess.TheIASLCplanstocontinuethisprojectin2016.

InDecember2014,CHEST,theAmericanSocietyforClinicalPathology,theNationalComprehensiveCancerNetwork®(NCCN®),IASLCandTheFranceFoundationdevelopedalivelearningexperiencecalledGAIN(EnGAgingAnInterdisciplinaryTeam)forNSCLCDiagnosis,PersonalizedAssessmentandTreatment.Throughcase-baseddiscussionsandinteractivesimulations,GAINinterdisciplinarysummitssoughttoaddressspecificunmetneedsandclinicalgapsinthecareofpatientswithlocallyadvancedandmetastaticnon-smallcelllungcancer(NSCLC).Thegoalofthesummitswastoadvancetheknowledge,competence,andperformanceofateamofinterdisciplinaryspecialistswhoarecurrentlyresponsibleforappropriatestaging,mediastinallymphnodeassessment,tissueacquisition,biomarkeranalysisandimmunotherapyinpatientswithNSCLC.Throughout2015, 12GAINeventswereheld:eightintheU.S.andfourinEurope.

Global Curricular FrameworkTheEducationCommitteedevelopedandmaintainsaGlobalCurricularFrameworkforthoraciccancer,categorizedaccordingtorelevantsubspecialtiesoftheIASLCmembership.EachofthesesubspecialtycurriculawasbasedonthestructureoftheIASLC-sponsoredTextbookofThoracicOncology.Thiscurriculum-basedframeworkisdesignedtoserveasafoundationfora“lifelonglearning”cultureintheIASLC.ItisenvisionedthateveryIASLC-sponsorededucationaleventwillbealignedwiththiscurricularframework,asitwillbeusedprospectivelytoidentifyeducationgaps,andtoplananddevelopmaterialsforworkshops,webinars,andIASLC-sponsoredliveeducationalevents.Thecurricularframeworkwillalsoserveasthereferenceclassificationsystem(ortaxonomy)fortheplannedIASLCon-lineeducationportal,wheresubspecialtycurriculawillbeusedtoorganizecontentandtagmaterials.Thiscurriculum-orientededucationportalwillalsoprovidecentralizedaccesstoarchivedliveanddistancelearningactivities,aswellasperformanceimprovementCMEmodules.Formoreinformation,pleasevisitiaslc.org.

Global Curricular Framework Categories: » Basic/TranslationalScience » MedicalOncology » Pathology

» PulmonaryMedicine » RadiationOncology » ThoracicSurgery


PublicationsThepastyearsawseveraloftheIASLC’sinitiativescometofruition.Wepubliclyunveiledthesenewpublicationsatthe16thWorldConferenceonLungCancerinSeptember.Allwillhelpusinourmissiontospreadbestpracticesaroundtheglobeandassisthealthprofessionalsintheirbattletoconquerthoraciconcologyworldwide.

New Staging SystemAsannouncedattheWCLC,thepublicationoftheEighthEditionoftheTumor,NodeandMetastasis(TNM)ClassificationofLungCancerwillprovidephysiciansaroundtheworldaccesstonewdatatomorepreciselystageandtreatcasesoflungcancer.Thedata,collectedbytheIASLCStagingCommittee,areplannedforpublicationin2016.

TheIASLChelpedpublishcardsthatexplainthedifferentpartsofthenewstagingsystemandwidelydistributedthemattheWCLC.

In1998,IASLCestablisheditsLungCancerStagingProject,anefforttocollectasignificant,internationaldatabaseoflungcancercasesandtheiranatomicalclassifications.IASLCcollectedandpublishedalargeamountofdataregardingthesizeoftumors,lymphnodeinvolvementandmetastaticstatuswhichwasthenpresentedtotheUnion

forInternationalCancerControl(UICC)andtheAmericanJointCommitteeonCancer(AJCC)forevaluation.BeforetheIASLCStagingProject,datacollectedforstagingoflungcancercamefromasmallergroupofpatients,almostexclusivelybasedintheU.S.

Thenewdatabase,whichwillinformtheEighthEditionoftheTNMClassificationofLungCancer,consistsof94,708patientsdiagnosedaroundtheworldfrom1999-2010.TheobjectiveistofurtherexploreandanalyzetheimpactonprognosisoftumorsizeandofthedifferentTdescriptors;theprognosticsignificanceoftumorburdeninhilarandmediastinallymphnodes;andtheconfirmationoftherevisedM1categories(M1aandM1b)oftheseventheditionoftheclassificationalongwiththeprognosticimpactofnumberandanatomiclocationofmetastases.

Thepreciseclinicaldescriptionofmalignantneoplasmsandhistopathologicalclassificationmayserveanumberofrelatedobjectives:

» Toaidtheclinicianintheplanningoftreatment

» Togivesomeindicationofprognosis

» Toassistinevaluationoftheresultsoftreatment

» Tofacilitatetheexchangeofinformationbetweentreatmentcenters

» Tocontributetothecontinuinginvestigationofhumancancer

20IASLC

AnalysesofthenewdatabaseandthefindingssuggestingrecommendationsfortherevisionoftheseventheditionoftheTNMclassificationoflungcancerwillbesubmittedtotheJournal of Thoracic Oncology to makethemavailabletotheworldwideoncologycommunity.ThesuggestedrecommendationsandtheirsupportivedatawillalsobesubmittedtotheUICCandtheAJCCfortheirassessmentandinclusionintheirnewstagingmanuals,duetobepublishedin2016.TheneweditionoftheclassificationwillthenbeenactedinJanuary2017.

2015 WHO Pathology ClassificationAnadditionalIASLCglobalinitiativeshowcasedattheWCLCincludedthereleaseofthe2015 WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (Fourth edition).WHOClassificationsrepresentapathologicandgeneticclassificationandgradingofhumantumorsdesignedtobeacceptedandusedworldwide.Theyprovidestandardcriteriaforpathologydiagnosis,clinicalpractice,cancerregistration,epidemiologicstudies,clinicaltrialsandcancerresearch.

The2015WHOClassificationofLungTumorsrepresentstheculminationofadecadeofremarkableadvancesinalllungcancerspecialtiesincluding:pathology(histology,cytology,immunohistochemistry,moleculartesting),clinicaloncology,epidemiology,radiologyandgenetics.Therapidexpansionofmolecularandimmunohistochemicaltoolsprovidedastrongfoundationfortheclassificationandarationaleforreclassificationofspecificentities.

Accuratepathologicdiagnosisandtissuemanagementisnowcriticalinlungcancerdiagnosisandmanagement.Historically,pathologistswerechargedwithdistinguishingbetweensmallcellcarcinomaandnon-smallcellcarcinoma,limitingtheirrole.Withtherapeuticandgeneticadvances(particularlyregardingtargetedtherapiesinpatientswithdrivermutationsinEGFR,ALK,ROS1,BRAFandRET)wheretreatmentstrategiesdependonhistologyandgenetics,pathologistsmustnowmakemoreprecisediagnosesandpreservetissueformoleculartesting.

PreviousWHOclassificationsdidnotfocusondiagnosisinsmallbiopsiesandcytology,sothisisacompletelynewaspecttothisWHOClassification.Criticalaspectsofthisinclude:

» Newdiagnosticcriteriaandterminologyforlungcancerinsmallbiopsiesandcytology

» Moreaccuratehistologicsubtyping

» Strategicmanagementofsmalltissues

» Streamliningworkflowformoleculartesting

» Localmultidisciplinarystrategyforobtaining,processingandreportingthesespecimens.


New Statement on Tobacco Control & Smoking CessationStemmingfromthefactthatthevastmajorityoflungcancercasesresultfromtobaccosmoking,theIASLCissuedanewstatementonTobaccoControlandSmokingCessationattheWCLC.Thestatementcallsforhighertaxesontobaccoproducts,comprehensiveadvertisingandpromotionbansofalltobaccoproductsandproductregulationincludingpackwarnings.

Asakeypartofthestatement,theIASLCTobaccoControlandSmokingCessationCommitteehighlightedanestimatethatshowedthatdoublingtheinflation-adjustedpriceofcigarettescouldresultina33percentreductioninsmokingprevalence.Manylow-andmiddle-incomecountriescanaccomplishthisbytriplingthespecificexcisetaxontobacco.Alow-specificexcisetaxontobaccoisthemainreasoncigarettesareabout70percentcheaperinmanylow-incomecountriescomparedwithhigh-incomecountries.

Inthestatement,theIASLCurgesitsmembersandothersaroundtheworldto:

» JointogethertoforcefullyimplementtheWHO’sFrameworkConventiononTobaccoControlwhichhasamongitskeyprovisionsincreasingcigarettepricesviataxation(toatleast70percentoftheretailprice),prohibitingthesaleofcigarettestominors(lessthan21yearsofage),enactingandenforcingcomprehensivecigarettemarketingpolicies,eliminatingtobaccouseinpubliclocations,mandatinggraphicwarninglabelsoncigarettecontainers,implementingpubliceducationcampaignstodiscouragetheuseofcigarettesandprovidingtobaccocessationsupport.

» Adoptlegalreformsthatallowpeoplewhosmokeandtheirfamiliestousethejudicialsystemtoholdtobaccomanufacturerscivillyandcriminallyaccountableforsellingproductsthataredeadlywhenusedasintended.

» Supportprogramstopreventsmokinginitiationhabitsinchildrenandinyouthandrecognizethatanyattemptstoinducenicotineconsumptioninthispopulationshouldbeavoided.

» Implementtobaccocessationprogramsintheirclinics,hospitalsandcancercenterstoassisttheirpatientsinachievingthebestpossibleoutcomesfromtheircancertreatment.

» Adoptpolicymeasuresthatrecognizetheprobabledifferencesinthelungcancerriskofalternativenicotinedeliveryproducts.Adoptingpoliciesthatfavorlessdangerous(non-combustible)formsofnicotinedeliveryovercigaretteswouldprovideapowerfulincentiveforpeoplewhosmoketomoveawayfromcigaretteswhichinturnwouldhaveaprofoundimpactongloballungcancerratesinthecomingdecades.

ReadthefullStatementonTobaccoControlandSmokingCessationat www.iaslc.org/research-education/policies.

22IASLC

Alex A. Adjei, MD, PhD, FACP, Editor-in-ChiefVolume 11, Number 1, January 2016

Journal ofThoracic Oncology

Of cial Publication of the International Association for the Study of Lung Cancer www.jto.org

JTHO_v11_i1_COVER.indd 1 08-12-2015 15:53:40

Journal of Thoracic OncologyTheJournal of Thoracic Oncology,theofficialjournaloftheIASLC,istheprimaryeducationalandinformationalpublicationfortopicsrelevanttothedetection,prevention,diagnosis,andtreatmentofthoracicmalignancies.JTOemphasizesamultidisciplinaryapproach,andincludesoriginalresearch(clinicaltrialsandtranslationalorbasicresearch),reviews,andopinionpieces.Ithasaglobalauthorbaseandreadershipconsistingofepidemiologists,medicaloncologists,radiationoncologists,thoracicsurgeons,pulmonaryspecialists,radiologists,pathologistsandresearchscientistswithaspecialinterestinthoraciconcology.

In2015,913originalresearcharticlesweresubmittedwithacceptanceof133,resultinginanacceptancerateof14.6percent.Forallsubmissiontypes,therewere1,276manuscriptssubmittedand216wereaccepted,equatinganacceptancerateof16.9percent.Therewere193,387full-textviewsand240,207websitevisitsin2015.The

JTOwasranked30outof211foroncologyand7outof57forrespiratorysystemsubjectmattercategoriesinthe2014JournalCitationReports.The2014ImpactFactorwas5.282,downslightlyfrom5.8in2013.The2015ImpactFactorissettobereleasedinJuly2016.

Startingin2016,ElsevierbecomesthenewpublisheroftheJTO.Alongwithanewlook,themovemakesmanynewfeaturesavailabletoourauthorsandreaders:

» ShareLinkallowsauthorstofreelydistributetheirpublishedarticlesfor50days

» ArticleswillbeaddedtoScopus,theworld’slargestabstractandcitationdatabaseof peer-reviewedliterature

» Acceptedmanuscriptswillbepostedwithinthreedaysofacceptance

» Publishedfindingscanbehighlightedwithaudioslidepresentations.

“Astheleadinginternationallungcancerassociation,theIASLCisexcitedtoexpandthereachoftheJTOandtoensurethatmedicalprofessionalsaroundtheworldhaveaccesstothecuttingedgeresearchbeingsharedinthispublication,”saidAlexA.Adjei,MD,PhD,Editor-in-ChiefoftheJTO.“WeareworkingcloselywiththeElsevierteamtomaximizethebenefitsthatElseviercanprovidetoauthorsandreadersoftheJTO.ThiswillallowustotakeadvantageofsynergieswithElsevier’selectronicinfrastructureandextensivecatalogofleadingcancerpublications.”


TheCommunicationsCommittee,MurryWynes,PhD,andtheIASLCScienceDepartmentcontinuetheireffortstopromotetheJTOthroughpressreleasessenttothemedia.ThiscollaborationhasresultedincoverageinThe New York TimesandotherpremieroutletsthusfurtheringtheeducationaloutreacheffortsoftheIASLC.ThenextpagesshowtheJTOarticlesfeaturedin2015.

JTO Articles Highlighted in Press Releases

Re-evaluation of the role of post-operative radiotherapy and the impact of radiation dose for non-small cell lung cancer using the National Cancer Database

ChristopherD.Corso,MD,PhD;CharlesE.Rutter,MD LynnD.Wilson,MD;AnthonyW.Kim,MD;RoyH.Decker,MD,PhD;ZainA.Husain,MD

Supportive care in lung cancer: Milestones over the past 40 years AlexMolassiotis,RN,PhD;WilmaUyterlinde,NP,PhD;PatriciaJ.Hollen,PhD,RN,FAAN; LindaSarna,RN,PhD;PatriciaPalmer,RN,MS,AOCNS;MeinirKrishnasamy,RN,PhD

Perception of Lung Cancer Among the General Population and Comparison With Other Cancers JulienMazières,MD,PhD;Jean-LouisPujol,MD,PhD;NikosKalampalikis,PhD;DianeBouvry,MD;ElisabethQuoix,MD,PhD;

ThomasFilleron,MD,PhD;NathalieTargowla,MD;DeniseJodelet,PhD;JulieMilia,PhD;BernardMilleron,MD

Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study

MarcoLoIacono,PhD;ValentinaMonica,PhD;LuisellaRighi,MD;FedericaGrosso,MD;RobertaLibener,MD;SimonaVatrano,BS; PaoloBironzo,MD;SilviaNovello,MD;LoredanaMusmeci,MD;MarcoVolante,MD;MauroPapotti,MD;GiorgioV.Scagliotti,MD

Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small Cell Lung Cancer DorothyRomanus,PhD;StephanieCardarella,MD;

DavidCutler,PhD;MaryBethLandrum,PhD;NealI.Lindeman,MD;G.ScottGazelle,MD,PhD

24IASLC

Baseline characteristics and mortality outcomes of NELSON control group participants and eligible non-responders UraujhYousaf-Khan,MD;NandaHoreweg,PhD,MD;CarlijnvanderAalst,PhD; KevintenHaaf,MSc;MathijsOudkerk,PhD,MD;HarrydeKoning,PhD,MD

Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma

ZoltanLohinai,MD;MirAlirezaHoda,MD;KatalinFabian,MD;GyulaOstoros,MD,PhD;ErzsebetRaso,PhD; TamasBarbai,MS;JozsefTimar,MD,PhD,DSc;IlonaKovalszky,MD,PhD;MihalyCserepes,MS;AnitaRozsas,MS; ViktoriaLaszlo,PhD;MichaelGrusch,PhD;WalterBerger,PhD;WalterKlepetko,MD;JuditMoldvay,MD,PhD;

BalazsDome,MD,PhD;BalazsHegedus,PhD

The presence of asbestos in the natural environment is likely related to mesothelioma in young individuals and women from Southern Nevada

FrancineBaumann,PhD;BrendaJ.Buck,PhD;RodneyV.Metcalf,PhD; BrettT.McLaurin,PhD;DouglasJ.Merkler,MSc;MicheleCarbone,MD,PhD

Impact of an Interactive Online Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small Cell Lung Cancer

HelenChow,MD;MartinJ.Edelman,MD;GiuiseppeGiaccone,MD;SureshS.Ramalingam,MD;TimothyA.Quill,PhD; AndrewD.Bowser,PhD;JimMortimer,PhD;WilmaGuerra,PhD;LaurelA.Beckett,PhD;

HowardL.West,MD;PrimoN.Lara,MD;DavidR.Gandara,MD

Patients selected for definitive concurrent chemoradiation at high-volume facilities achieve improved survival in stage III non-small cell lung cancer

ElynH.Wang,BS;CharlesE.Rutter,MD;ChristopherD.Corso,MD,PhD;RoyH.Decker,MD,PhD; LynnD.Wilson,MD,MPH;AnthonyW.Kim,MD;JamesB.Yu,MD,MHS;HenryS.Park,MD,MPH

Randomised study on early detection of lung cancer with MSCT in Germany: results of the first 3 years of follow-up after randomization

N.Becker,PhD;E.Motsch,MD;M.-L.Gross,MD;A.Eigentopf,BSc;C.P.Heussel,MD,PhD;H.Dienemann,MD,PhD; P.A.Schnabel,MD,PhD;M.Eichinger,MD;D.-E.Optazaite,MD;M.Puderbach,MD,PhD;

M.Wielpütz,MD;H.-U.Kauczor,MD,PhD;J.Tremper,MD;S.Delorme,MD,PhD

FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small Cell Lung Cancer

WoocheolKwon,MD;BrandonA.Howard,MD,PhD;JamesE.Herndon,PhD;EdwardF.Patz,Jr.MD

Increasing Physical Activity and Exercise in Lung Cancer: Reviewing Safety, Benefits, and Application BrettC.Bade,MD;D.DavidThomas,MS;JoAnnB.Scott,BA;GerardA.Silvestri,MD,MS

Hormone use, reproductive history and risk of lung cancer: the Women’s Health Initiative Studies AnnG.Schwartz,PhD,MPH;RobertaM.Ray,MS;MicheleL.Cote,PhD;JudithAbrams,PhD;RobertJ.Sokol,MD;

SusanL.Hendrix,DO;ChuChen,MS,PhD;RowanT.Chlebowski,MD,PhD;F.AllanHubbell,MD,MSPH; CharlesKooperberg,PhD;JoAnnE.Manson,MD,DrPH;MaryJoO’Sullivan,MD,DrPH;ThomasRohan,MBBS,PhD;

MarciaL.Stefanick,PhD;JeanWactawski-Wende,PhD;HeatherWakelee,MD;MichaelS.Simon,MD,MPHS


Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients

KatharinaKönig,PhD;MartinPeifer;JanaFassunke,PhD;MichaelaA.Ihle,Dipl-Biol;HelenKünstlinger,Dpil-Biol; CarinaHeydt,MSc;KatrinStamm,PhD;FrankUeckeroth;ClaudiaVollbrecht,BSc;MarcBos,MD;MasyarGardizi,MD;

MatthiasScheffler,MD;LuciaNogova,MD;FraukeLeenders,MD;KerstinAlbus,MSc;LydiaMeder,MSc; KerstinBecker,PhD;AlexandraFlorin,MA;UrsulaRommerscheidt-Fuss;JanineAltmüller,PhD;

MichaelKloth,MD;Nürnberg,PeterProf;ThomasHenkel,PhD;Sven-ErnöBikár,PhD;MartinL.Sos,PhD; WilliamJ.Geese,PhD;LewisStrauss;Yon-DschunKo,MD;UlrichGerigk,MD;MargareteOdenthal,PhD;

ThomasZander,MD;JürgenWolf,Prof;SabineMerkelbach-Bruse,MD; ReinhardBuettner,MD;LukasC.Heukamp,PhD,MD

Tobacco Cessation May Improve Lung Cancer Patient Survival KatharineA.DobsonAmato,MPH,PhD;AndrewHyland,PhD;RobertReed,MPH;MartinC.Mahoney,MD,PhD;

JamesMarshall,PhD;GaryGiovino,PhD;MaansiBansal-Travers,PhD;HeatherM.Ochs-Balcom,PhD;MichaelA.Zevon,PhD; K.MichaelCummings,PhD;ChukwumereNwogu,MD,PhD;AnuragK.Singh,MD;HongbinChen,MD,PhD;

GrahamW.Warren,MD,PhD;MaryReid,PhD

Safety and Efficacy of Buparlisib (BKM120) in Patients With PI3K Pathway-Activated Non-Small Cell Lung Cancer (NSCLC): Results From the Phase II BASALT-1 Study

JohanF.Vansteenkiste,MD,PhD;Jean-LucCanon,MD;FilippoDeBraud,MD;FrancescoGrossi,MD;TommasoDePas,MD; JhanelleE.Gray,MD;Wu-ChouSu,MD;EnriquetaFelip,MD,PhD;HiroshigeYoshioka,MD;CesareGridelli,MD;

GraceK.Dy,MD;SumitraThongprasert,MD;MartinReck,MD,PhD;PaolaAimone,MD;GenaAtallaVidam,MS,CPM; PanteliaRoussou,PhD;YingA.Wang,PhD;EmmanuelleDiTomaso,PhD;Jean-CharlesSoria,MD,PhD

Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor

SaiF.Yeung,BSc;JoannaTong,H.M.PhD;PeggyLaw,P.W.MPhil;LauY.Chung,AD;Lung,W.M.RaymondPhD; CarolTong,Y.K.MPhil;ChitChow,PhD;AnthonyChan,W.H.FRCPA;InnesWan,Y.P.FRCS;

TonyMok,S.K.MD;KaF.To,FRCPA

Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non–Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens

LuisPaz-Ares,MD;VeraHirsh,MD;LiZhang,MD;FilippodeMarinis,MD;JamesChih-HsinYang,MD; HeatherA.Wakelee,MD;TakashiSeto,MD;Yi-LongWu,MD;SilviaNovello,MD;ErszébetJuhász,MD;OsvaldoArén,MD;

YanSun,MD;ThomasSchmelter,PhD;TengJinOng,MD;CarolPeña,PhD;EgbertF.Smit,PhD;TonyS.Mok,MD

26IASLC

Fred R. Hirsch WCLC2015Congress

PresidentUniversityofColorado

James JettWCLC2015Congress

Co-ChairNationalJewishHealth

Harvey PassWCLC2015Congress

Co-ChairNYULangone MedicalCenter

Everett Vokes WCLC2015Congress

Co-ChairTheUniversityofChicagoMedicine

President and Co-Chairs

MeetingsIASLCmembersandstaffworktoenhancetheunderstandingoflungcanceramongscientists,membersofthemedicalcommunityandthepublic.Oneofthemosteffectivewaysthatthisisaccomplishedisbyofferingcutting-edgeeducationalmeetingsaroundtheglobe.

The16thWorldConferenceonLungCancer(WCLC),heldSept.6-9inDenver,Colorado,wasahugesuccess.

2015 IASLC World Conference on Lung CancerIASLC’sbannereventof2015wasthe16thWorldConferenceonLungCancer(WCLC)heldinDenver,Colorado,USAinearlySeptember.Morethan6,000researchers,physiciansandspecialistsfromnearly100countriescametogethertolearnandshareinformationaboutlungcancer.

Theconferenceistheworld’slargestmeetingdedicatedtolungcancerandotherthoracicmalignanciesandcoversawiderangeofdisciplines,includingmorethan300invitedtalksand3,000formalresearchstudiesandclinicaltrialresults.EverypresentationateachWCLCaimstoincreaseawarenessandcollaborationsosurgeons,medicaloncologists,radiationoncologists,pulmonologists,radiologists,pathologists,epidemiologists,basicresearchscientists,nurses,alliedhealth

professionals,advocates,caregiversandpatientsunderstandthelatestdevelopmentsandcanimplementthemthroughouttheworld.

WELCOME TO THE IASLC

16TH WORLD CONFERENCE ON LUNG CANCER

Conference Program Book

FOLLOW US ON TWITTER @IASLC #WCLC2015

FOLLOW US ON FACEBOOK

WWW.IASLC.ORG

BECOME A MEMBER OF IASLC VISIT WWW.IASLC.ORG


DaraAisner UniversityofColorado

BrianKavanagh UniversityofColorado

AnnaBaron UniversityofColorado

RobertKeith UniversityofColorado

PaulA.Bunn,Jr. UniversityofColorado

JeffreyKern NationalJewishHealth

TimByers UniversityofColorado

EviMakovsky PatientAdvocate

D.RossCamidge UniversityofColorado

DanMerrick UniversityofColorado

LaurieCarr NationalJewishHealth

YorkMiller UniversityofColorado

RobertDoebele UniversityofColorado

JohnMitchell UniversityofColorado

WilburFranklin UniversityofColorado

AnaOton UniversityofColorado

MarileilaVarella-Garcia UniversityofColorado

DavidRaben UniversityofColorado

KavitaGarg UniversityofColorado

MichaelWeyant UniversityofColorado

LaurieGaspar UniversityofColorado

SamirWitta MountainBlueCancerCareCenter

RobertJotte RockyMountainCancerCenters

Local Organizing Committee

Forthefirsttime,thisyear’sconferenceincludedlungcancerpatients,survivorsandcaregivers.Additionally,theconferencesawthereleaseofIASLC’snewTobaccoControlandSmokingCessationStatement(seepage21)andtheculminationoftwomajorIASLCinitiatives:theEighthEditionoftheTumor,NodeandMetastasis(TNM)ClassificationofLungCancer(page19)andThe WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (Fourthedition)(page20).

ThisWCLCalsofeaturedthefirsteverFunWalkandPancakeBreakfast.Around300peopleparticipated,includinglungcancerpatients,healthprofessionals,patientadvocatesandmore.Theeventraisednearly$20,000fortheIASLCFoundation.

The2015WCLCalsomarksthebeginningofanewerafortheIASLC.Insteadofeverytwoyears,wewillnowhosttheWCLCannually.The17thWCLCissettotakeplaceinDecember2016inVienna,Austria,andthe18thWCLCwillbeinYokohama,JapaninOctober2017.

28IASLC

WCLC 2015 By the Numbers » More than 6,000 attendees » From nearly 100 countries » 2,122 abstracts submitted » 258 oral abstracts presented » 437 mini-oral abstracts presented » 1,213 poster presentations » 89 invited sessions

Medical Oncology

Other

Thoracic Surgery

Pulmonary Medicine

Cancer Research

Radia�on Oncology

Nursing

Pathology

Basic Sciences

Pharmacy

Diagnos�c Radiology

Advocacy

Biosta�s�cs

Hermatology

Smoking Cessa�on

0%

10%

20%

30%

40%

50%

60%

Europe North America Asia Rest of the World

Medical Oncology

Other

Thoracic Surgery

Pulmonary Medicine

Cancer Research

Radia�on Oncology

Nursing

Pathology

Basic Sciences

Pharmacy


Advocacy

Biosta�s�cs

Hermatology

Smoking Cessa�on

0%

10%

20%

30%

40%

50%

60%


Demographic Distribution

Specialties of Delegates

Medical Oncology

Other

Thoracic Surgery

Pulmonary Medicine

Cancer Research

Radia�on Oncology

Nursing

Pathology

Basic Sciences

Pharmacy


Advocacy

Biosta�s�cs

Hermatology

Smoking Cessa�on

0%

10%

20%

30%

40%

50%

60%



Best of IASLC WCLC 2015

Location Date Organizer/ChairTurin,Italy September2015 SilviaNovello

Florence,Italy September2015 SilviaNovello

Bari,Italy September2015 SilviaNovello

SanFrancisco,USA October2015 DavidGandara

Paris,France October2015 ThierryleChevalier

Oslo,Norway October2015 OddTerjeBrustugun

TheNetherlands October2015 QuadiaGroup

Guangdong,China October2015 ChineseThoracicOncologyGroup

Yokohama,Japan November2015 JapanLungCancerSociety

Prague,CzechRepublic November2015 CentralEuropeanLungCancerGroup

Salvador,Brazil December2015 LatinAmericanCooperativeGroup

Athens,Greece January2016 KonstantinosSyrigos

Seoul,Korea January2016 KeunchilPark

Lima,Peru February2016 GrupodeEstudiosClinicoPeruano

BuenosAires,Argentina March2016 EduardoRichardet

Cancun,Mexico March2016 MauroMolinaVargas

Best of WCLC 2015ForthosenotabletoattendtheWCLC,IASLCcontinuestogrowandexpandthe“BestofWCLC”events–educationalinitiativeswhichcondensethetimeliestscientificandeducationaltopicsfrommultipledisciplinesintoaone-dayeventandheldthroughouttheworldin2015.IASLCpartneredwithlocalexpertswhocraftedtheagendasandfocusedonWCLCcontenttomeettheirregionalneeds.

30IASLC

IASLC Meetings in 201515th Annual Targeted Therapies of the Treatment of Lung CancerThisinvitation-onlymeetinggatheredthetopscientiststodiscussthelatestadvancesinthetreatmentoflungcancerwithtargetedtherapies.February 18 – 21, 2015 | Santa Monica, CA Chairs:PaulA.Bunn,Jr.,DavidH.Johnson andRoyHerbst#Participants:450

European Lung Cancer Conference (ELCC)TheEuropeanSocietyofMedicalOncology(ESMO)andtheIASLCorganizedtheELCC,bringingtogetherthetopacademicexpertsinlungcancerandthoracicmalignanciestoshowcasethelatestdevelopmentsinbasic,clinicalandtranslationalresearch.

April 15-18 2015 | Geneva, Switzerland Chairs:DominiqueGrunenwald,FranceandJohanVansteenkiste,Belgium#Participants:1650

Small Cell Lung Cancer TwohundredglobalexpertsinSCLCmettoreviewandrefocusthefield,tofostercollaborationwiththegenerationofnewandinnovativeideasforbasicandclinicalresearch,andtohighlightthepotentialroleforpersonalizedmedicineinSCLCclinicaltrialdesigns.Areviewpublicationfromthismeetingwillbepublishedin2016.April 22-24, 2015 | New York, NYChairs: CharlesRudin,FredR.Hirsch,PaulA.Bunn,Jr.,JohnMinna,GlenwoodGoss,RomanThomas,PeterUjhazy,WolfLindwasser,andShakunMalik#Participants:200

EGFR Expert MeetingAgroupofmultidisciplinaryexpertsincludingpathologists,pulmonologists,medicaloncologists,thoracicsurgeons,radiationoncologists,anddiagnosticradiologistsmettodiscusshowbesttoguidethelungcancercommunitiesonmoleculartestingandclinicalmanagementofpatientswithEGFRmutatedNSCLC,whohaveprogressedonfirst-lineEGFRTKItherapyforadvanceddisease.August 1, 2015 | Huntington Beach, CAChair: FredR.Hirsch#Participants:20


BTOG 2015BritishThoracicOncologyGroup(BTOG)13thAnnualConferenceJanuary 28-30, 2015 | Dublin, Ireland

2015 Lung Cancer Workshop XIIPreventCancerFoundationMay 4-5, 2015 | Bethesda, MD

23rd European Conference on General Thoracic SurgeryEuropeanSocietyofThoracicSurgeonsMay 31-June 3, 2015 | Lisbon, Portugal

16th Annual International Lung Cancer CongressJuly 30 - August 1, 2015 | Huntington Beach, CA

4th Congress of Respiratory MedicineInstituteforPulmonaryDiseasesofVojvodinaMedicalFaculty,UniversityofNoviSadandClinicforPulmonology, ClinicalCenterofSerbiaOctober 15-18, 2015 | Novi Sad, Serbia

Eighth Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung CancerBioMedicalLearningInstitute(BMLI)October 17, 2015 | San Francisco, CA

International Conference on Mesothelioma in Populations Exposed to Naturally Occurring Asbestiform FibersChairman:MicheleCarboneNovember 9-10, 2015 | Honolulu, HI

CELCC 201515thCentralEuropeanLungCancerConferenceNovember 28-30 2015 | Prague, Czech Republic

IASLC Endorsed and Supported Meetings in 2015

32IASLC

Inter-Disciplinary Workshop to Enhance Assessment and Management of Lung CancerIDEALWorkshopDecember 4, 2015 | Singapore

9th Annual ConferencePolishLungCancerGroupNovember 6-7, 2015 | Warsaw, Poland

2nd International Conference AsiaThoracoscopicSurgeryEducationProgram(ATEP)December 4-5, 2015 | Seoul, Korea

4th AACR-IASLC International Joint ConferenceThetranslationalsciencefeaturedatthisconferencewillincludethefoundationofbasicresearchthatbeginsatthebenchandcontinuesthroughpatientcareintheclinic.January 4 – 7, 2016 | San Diego, CA Moredetailsonwww.iaslc.org

16th Annual Targeted Therapies of the Treatment of Lung CancerThisinvitation-onlymeetinggathersthetopscientiststodiscussthelatestadvancesinthetreatmentoflungcancerwithtargetedtherapies.February 17 – 20, 2016 | Santa Monica, CA Moredetailsonwww.iaslc.org

European Lung Cancer Conference (ELCC)TheEuropeanSocietyofMedicalOncology(ESMO)andtheIASLCorganizetheELCC,bringingtogetherthetopacademicexpertsinlungcancerandthoracicmalignanciestoshowcasethelatestdevelopmentsinbasic,clinicalandtranslationalresearch.April 13-16 2016 | Geneva, Switzerland Moredetailsonwww.iaslc.org

2016 Meetings and Events


IASLC Asia Pacific Lung Cancer Conference (APLCC 2016)Theconferencewillbringyouinformationinfrontiersofclinicalandbasicresearches,practicalclinicalmanagement,andmultidisciplinarycarefromWesternandAsia-Pacificfaculties.May 13 - 16 2016 | Chiang Mai, Thailand Moredetailsonwww.iaslc.org

2016 IASLC Latin American Lung Cancer Conference (LALCA)InternationalandnationalspeakerswilldiscussthescienceandadvancesinthetreatmentandpreventionoflungcancerandthoracicmalignanciesworldwideandinLatinAmericainparticular.August 25 - 27 2016 | Panama City, Panama Moredetailsonwww.iaslc.org

IASLC Chicago Multidisciplinary Symposium in Thoracic OncologyCo-chairs: FredR.Hirsch,MD,PhD& EverettVokes,MD.September 22-24 2016 | Chicago, IL Moredetailsonwww.iaslc.org

17th IASLC World Conference on Lung CancerTheWorldConferenceonLungCancer(WCLC)istheworld’slargestmeetingdedicatedtolungcancerandotherthoracicmalignancies.Morethan6,000delegatescomefromnearly100countriestodiscussthelatestdevelopmentsinthoracicmalignancyresearch.

December 4-7 2016 | Vienna, Austria Moredetailsonwww.iaslc.org

34IASLC

TheMary J. Matthews Pathology/Translational Research AwardisgiventoanIASLCscientistforlifetimescientificachievementsinpathology-translationalresearchofthoracicmalignancies.Dr.MingTsaoreceivedthisawardfor2015. Dr.Tsao’sprimarygoalinlungcancerresearchistoidentifygenesorproteinsthatarepredictiveofpoorprognosisinlungcancerpatientswhohavehadtheirtumorsresectedbysurgery.Hiscurrentlungcancerresearchactivitiesincludebiomarkersintargetedcancertherapy,molecularprognosticandpredictivemarkersandpathobiologyoflungcancer,tumorcellstromalinteraction,Rasoncogene,andapplicationofnoveloptical/Ramantechnologiesfortissue/cellularandinvivoimaging.Dr.TsaohasservedontheEditorialBoardoftheJTOandasamemberoftheInternationalProgramCommitteeforthreeWCLCs.

TheJoseph W. Cullen Prevention/Early Detection AwardisgiventoanIASLCscientistforlifetimescientificachievementsinpreventionresearchofthoracicmalignancies.Dr.JacekJassemheadstheDepartmentofOncologyandRadiotherapyattheMedicalUniversityofGdansk,Poland.Hisdepartment’sresearchunitfocusesonclinicaltrialsandtranslationalresearchcombiningcancermolecularfeatureswithclinicalbehavior.Theteamhasdevelopedandvalidatednoveltumorbiomarkersinlungcancerandbreastcancer,andsharesalongtermcollaborationwiththeUniversityofColorado,publishinginthefieldofpredictiveassaysforthepotentialbenefitsoftargetedtherapiesinlungcancer. Dr.JassemisamemberoftheIASLCTobaccoControlandSmokingCessationCommitteeandactivelyadvisesothercountriesonthistopic.

IASLC 2015 Distinguished AwardsTheIASLChasfourdistinguishedawardswhichwerepresentedatthe2015WorldConference onLungCancer(WCLC).

ThePaul A. Bunn, Jr. Scientific AwardisgiventoanIASLCscientistforlifetimescientificcontributionsinthoracicmalignancyresearchandwhohasalsocontributedtotheorganization’sdevelopment.Dr.Yi-LongWu’smainresearchinterestsarethemultidisciplinarysynthetictherapyonlungcancerfrombasicsciencetobedsideandevidence-basedmedicineinoncology.Hisresearchmainlyfocusesonclinicalandbasicstudyofcombinedtreatmentofnon-smallcelllungcancer(NSCLC),especiallyinprofilingthelungcancertumorsinChinesepatientsfordriveroncogenesandtobuildatumortissuebankacrossChina,connectedbyacomputersystem.HeisaleaderintheChineselungcancerfieldandhasbeenaPrincipalInvestigatororCo-PIinmorethan90multi-centerclinicaltrials.Hehascontributed20booksoncancerandhaspublishedmorethan300articlesinpeer-reviewedjournals.Dr.WualsoservesontheIASLCBoardofDirectors.

The IASLC Merit Award isgiventoamemberofIASLCwhohasmadeanextraordinarycontributiontotheorganization’sdevelopment.Dr.HarveyPassreceivedthe2015IASLCMeritAwardforhisworkasasurgeonscientistfocusingontheearlydetection,surgicalmanagementandadjuvanttherapyofthoracicmalignancies.Dr.PasshasbeencontinuouslyfundedbytheDOD,NCI,andtheCDCamongotherssince1998forthediscoveryandvalidationofblood-basedbiomarkersincludingosteopontin,solublemesothelinrelatedprotein,andfibulin3.Dr.Passhaspublishedover450peer-reviewedpublications,11books,includingtheIASLCMultidisciplinaryApproachtoThoracicOncology,andservesasaneditorandonmanyeditorialboards.Dr.PasshasbeenanactivememberoftheIASLCsince1998,servingasthechairofthePublicationsCommitteeandtheCo-Chairofthe2015WCLCLocalOrganizingCommitteeamonghisotherroles.

Dr. Harvey PassUSA

2015 IASLC Merit Award

Dr. Yi-Long WuChina

Paul A. Bunn, Jr. Scientific Award

Dr. Jacek JassemPoland

Joseph W. Cullen Prevention/Early Detection Award

Dr. Ming TsaoCanada

Mary J. Matthews Pathology/ Translational Research

Award


IASLC WCLC 2015 Developing Nation AwardsAsrecipientsofthe2015DevelopingNationAwards,tenresearchersfromsixdevelopingnationsreceivedsupporttoattendtheWCLCinDenver,Colorado.

Recipient Institution CountryBernadetteReynaAsuncion DeLaSalleUniversity PhilippinesMaríaCastillo INCan MexicoXiangkunHan ChineseAcademyofSciences ChinaTomiKovacevi InstituteforPulmonaryDiseasesofVojvodina,Facultyof

Medicine,UniversityofNoviSadSerbia

SatyaNarayan AcharyaTulsiRegionalCancerTreatmentandResearchInstitute IndiaBlessingObiazi-Odiase ChildrenLifeAdvancementProject NigeriaEmmanuelOdiase NigerianCancerSociety NigeriaCristinaPerez NationalCancerInstituteofBrazil BrazilMalcolmTagbarha UniversityofAbuja NigeriaQiWang TheSecondAffiliatedHospitalofDalianMedicalUniversity China

IASLC WCLC 2015 Young Investigator AwardsIASLCYoungInvestigatorAwardsaregiventorewardscientificexcellenceandtoencourageinnovativeresearchinlungcancerpreventionandtranslationalmedicineworldwide.TheawardsareopentoIASLCmemberswhoarewithinthreeyearsofaninitialfacultyappointmentatthetimeofapplicationandwithinthreeyearsofcompletionoffellowship/postdoctoraltraining.

Recipient Institution CountryLynnetteFernandez-Cuesta InternationalAgencyforResearchonCancer FranceYoshihisaKobayashi KinkiUniversityFacultyofMedicine JapanJiYunLee SamsungMedicalCenter SouthKoreaClaraPérez-Rambla CentrodeInvestigaciónPríncipeFelipe SpainTomaszPowrózek MedicalUniversityofLublin PolandBrandonSheffield UniversityofBritishColumbia CanadaKenichiSuda KinkiUniversityFacultyofMedicine JapanDanaTsui UniversityofCambridge EnglandDaweiYang ZhongshanHospitalFudanUniversity ChinaWenjingZhang ChineseAcademyofSciences China

36IASLC

Recipient Role LocationHildrethGrossman President/Founder,UpstageLungCancer Brookline,MassachusettsSedaKansu Co-founder,PembeHanim Istanbul,TurkeyVictorLasebikan PsychiatristandLecturer,UniversityofIbadan Nigeria,AfricaKathleenMewhiney Founder/President,TheJohn&AmyMewhineyCancer

FoundationSilverSpring,Maryland

DanPowell LungCancerSurvivor/PatientAdvocate Greenville,SouthCarolinaTetsuyaYamaoka LungCancerSurvivor/PatientAdvocate Tokyo,Japan

Award Recipient AbstractAdiGazdarLectureshipAward(TranslationalResearch)

LynnetteFernandez-Cuesta,PhD “GenomicCharacterizationofLargeCellNeuroendocrineLungTumors”

RobertGinsbergLectureshipAward(Surgery)

VirginieWesteel,MD “CompliancewithFollow-UpProgramsafterSurgeryforNon-SmallCellLungCancerinthePhaseIIIIFCT-0302Trial”

HeineHansenLectureshipAward(SmallCellLungCancer)

CharlesRudin,MD,PhD “ADLL3-TargetedADC,RovalpituzumabTesirine,DemonstratesSubstantialActivityinaPhaseIStudyinRelapsedandRefractorySCLC”

DanIdheLectureshipAward(MedicalOncology)

JohnEdwards,MD “QualityofResectioninPathologicalN2NSCLCinthePhase3LungAdjuvantRadiotherapyTrial(LungART):AnImportantFactor”

CliftonMountainLectureshipAward(Staging)

EdwardRobbins,MD “EvolutionintheSurgicalCareofNon-SmallCellLungCancer(NSCLC)PatientsintheMid-SouthQualityofSurgicalResection(MS-QSR)Cohort”

TsuguoNarukeLectureshipAward(Surgery)

RyutaroKakinuma,MD “NaturalHistoryofPulmonarySubsolidNodules:AProspectiveMulticenterStudy”

IASLC WCLC 2015 Advocacy Awards

IASLC WCLC 2015 Lectureships

TheIASLCWCLC2015AdvocacyAwardsaredesignedtoincreaseconnectionswithpatientadvocatesandadvocacyorganizationsaroundtheworld.Aninternationalpanelselectedtheawardwinnersfortheirleadershipinsupportinglungcancerresearch,patientsandawarenessworldwide.

TheIASLCrecognizedsixinvestigatorswithIASLCWCLC2015LectureshipAwardsfortheirhigh-rankingabstractsinkeyareasoflungcancer.TheseawardsarenamedafterIASLCmemberswhohavebeenleadersintheirfields.


IASLC would like to thank the following supporters of the IASLC 2015 International Mentorship Award Program:

Astellas • AstraZeneca • Bristol-Myers Squibb • Clovis • Merck • Novartis

IASLC WCLC 2015 International Mentorship AwardsTheInternationalMentorshipProgram,anew2015IASLCinitiative,isaprofessionaldevelopmentand educationprogramforearly-careerphysicians/researchersstudyingthoracicmalignanciesfrom economically-developingcountries.Theawardeesarematchedwithwell-establishedscientificandclinicalmentorsfromwithinthehostingWCLCregionandvisitthementor’sinstitutionforapproximatelyaweekfollowingtheWCLC.

Recipient Country MentorRafaelBitton Brazil SureshRamalingamSaulCamposGomez Mexico CharlesRudinJulianoCeCoelho Brazil RamaswamyGovindanRaniaAly Egypt WilliamTravisMariaJoseLabanca Argentina MarileilaVarella-GarciaZoltanLohinai Hungary PaulA.Bunn,Jr.DanielaMorales-Espinosa Mexico DavidCarboneAhmedNagy Egypt FredR.Hirsch/TheresaBoyleShengxiang“Harry”Ren China RossCamidgeSoumyajitRoy India KavitaGargPhanninTiraswasdichai Thailand AlexAdjeiLongJiang China JohnMitchellRajaramBurrah India JessicaDonington

Mentees with IASLC leadership at WCLC 2015

38IASLC

LungCancerFoundationofAmerican(LCFA)-FellowshipPartner

PreventCancerFoundation-FellowshipPartnerAddarioLungCancerFoundation-FellowshipPartner

AmericanLungAssociation(Colorado)CaringAmbassadorsLungCancerProgram

ChrisDraftFamilyFoundationCliftonF.MountainFoundation

DustyJoyFoundationEX:Re-learnLivewithoutCigarettes

FreeMeFromLungCancerFreetoBreathe

GlobalLungCancerCoalitionGlobalResourceforAdvancingCancerEducation

(GRACE)

InternationalThoracicOncologyNursingForumJohn&AmyMewhineyCancerFoundation

LungCancerAllianceLungCancerResearchFoundation

LungFoundationAustraliaLungevityFoundation

MesotheliomaAppliedResearchFoundationMyCancerGenome

PatientsRisingPembeHanim

UICCGlobalCancerControlCommunityUnionforInternationalCancerControl-UICC

UpstageLungCancerWomenAgainstLungCancerinEurope

AbbVieAriadPharmaceuticals

AstellasPharmaAstraZenecaBiodesix

BoehringerIngelheimBristol-MyersSquibb

CelgeneClovisOncologyDaiichiSankyo

EliLillyElekta

HelsinnTherapeutics

IlluminaJanssenPharma

MerckMyriadNovartisPfizer

Roche/GenentechSyntaPharmaceuticals

VentanaMedicalSystemsVerastemVertex

Pharmaceuticals

2015 SponsorsWe want to thank our sponsors for their generosity and support:

2015 Advocacy Partners


Strategic PlanThe mission of the IASLC is:

» Toembracethestudyoftheetiology,epidemiology,prevention,diagnosis,treatmentandallotheraspectsoflungcancerandotherthoracicmalignancies,

» ToprovideeducationandinformationaboutlungcancerandotherthoracicmalignanciestoIASLCmembers,tothemedicalcommunityatlarge,andtothepublic,and,

» Touseallavailablemeanstoeliminatelungcancerandotherthoracicmalignanciesasahealththreatfortheindividualpatientandthroughouttheworld.

TheIASLCBoardofDirectorsapprovedanambitiousstrategicplanfortheorganizationin2011afterasix-monthprocess.IASLCstaffstilladherestothisplan,eachyearidentifyingnumerousactionitemsrequiredtomakesignificantstepstowardachievingtheplan.In2015,IASLCstaffandmembersconductedtheactivitiesbelowtosupportthestrategicplanand ourmission.

StudyGOAL 1 – IASLC embraces the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies.

» TheIASLCStagingCommitteedevelopedthe8thEditionoftheStagingofLungCancer.WithnewclassificationsinMesotheliomaandThymicmalignancies,thenewclassificationsarethemostcomprehensiveever.

» TogetherwiththeWHO,theIASLCPathologyCommitteedevelopedthenew2015 WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (Fourth edition).TheIASLCisalsoworkingonneweditionsoftheAtlasofALKTestinginLungCancerandonaPD-L1Atlastoguideimmunotherapy.

40IASLC

» The2015WorldConferenceonLungCancer(WCLC)inDenverhadthemostcomprehensivetobaccocontrolandsmokingcessationprogramforanyworldconference,andincludedthelaunchoftheTobaccoControl andSmokingCessationCommittee’supdatedIASLCStatementonTobaccoControlandSmokingCessation.TheIASLCsignedontomultiplepolicylettersrelatedtotobaccocontrolin2015.

» TheIASLCPrevention,ScreeningandEarlyDetectionCommitteeheldanall-day,sold-outworkshoponplanningfortheimplementationoflungcancerCTscreeninginternationallyatWCLC2015.Committeemembersalsocreatedastandardizedapproachtoestablishinglungcancerscreeningclinics,toensureworldwideconsistency.Committeememberswroteadocumentonestablishingalungcancerscreeningclinic,withtheaimofhelpingcentersthroughastandardizedapproach.

EducationGOAL 2 - IASLC provides education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large and to the public.

» IASLChostedasuccessfulWorldConferenceonLungCancer(WCLC)inDenver,highlightinggroundbreakingscienceandexpandingattendancetopatientsandadvocatesaswellashealthprofessionals.TheIASLCwillnowhosttheWCLCeveryyear,continuingin2016inVienna,Austria,inYokohama,Japanin2017,inToronto,Canadain2018andinBarcelona,Spainin2019.

» IASLCuseditsrecentaccreditationtoofferexpandedandenhancedCMEatmanyof ourevents.

» IASLCcontinuedtobuilditseducationalwebinars,offeringmorewebinarsonmoretopicsandacrossmoretimezonesthan everbefore.


» TheEducationCommitteedevelopedmultidisciplinarycurriculumforfellowsandyounginvestigators,evaluatedrequestsforIASLCendorsedmeetingsanddevelopedLiveLearningProgramswhichwereinitiatedin2015andwillcontinueinthefuture.

» IASLCinitiatedanewseriesofthe“BestofWCLC”inthefallof2015.Withthehelpoflocalexperts,IASLCprovidedthemostsignificantupdatesfromtheWCLCtohundredsofparticipantsin18internationallocationswhowereunabletoattendtheWCLC inDenver.

» TheIASLC,alongwithExecutiveEditor HarveyI.Pass,MD,initiatedworkonaneweditionoftheIASLCMultidisciplinaryApproachtoThoracicOncologytextbooksetforpublicationin2016.

» » » » » » » » » »

»

Research and ScienceGOAL 3—IASLC advances research and science towards reducing the burden of thoracic malignancies worldwide.

» IASLCcontinuesitsfundingoffellowshipstopromotescientificexcellenceandtoencourageinnovativeresearch.ThisyearIASLCsupported11fellowsinitsprogram,continuedaChinesefellowshipandpartneredwiththeBonnieJ.AddarioFoundationtocreatealargefellowshipforthepreventionandearlydetectionof lungcancer.

» TheIASLCJournal of Thoracic Oncology continuedtoexpanditscoverageofthetoptranslationalandbasicresearchandaddedsignificantlytoitssubscriberbasewhilefinalizingadealwithanewpublisher,Elsevier.Alongwithanewlook,themovemakes manynewfeaturesavailabletoourauthorsandreaders.

» TheJTOwasranked30outof211foroncologyand7outof57forrespiratorysystemsubjectmattercategoriesinthe2014JournalCitationReports.The2014ImpactFactorwas5.282.

» Withthelargestattendanceever,theIASLC15thAnnualTargetedTherapiesintheTreatmentofLungCancerinSantaMonica,Calif.inFebruarygatheredtopscientiststodiscussthelatestadvancesinthetreatmentoflungcancerwithtargetedtherapies.

» TheyearalsosawasuccessfulEuropeanLungCancerConference(ELCC)inAprilandanannouncementfromIASLCandESMOthattheELCCwillbecomeanannualmeeting.

» IASLCalsoheldfocusedmeetingslikeoneonSmallCellLungCancerinNewYorkinApril2015andanEGFRmeetinginHuntingtonBeach,Calif.inAugust2015.

» ThePatientAdvocatesCommitteelaunchedseveralnewinitiativesincludingaPatientAdvocacyTrackatWCLC,uniqueregistrationratesforadvocates,survivorsandadvocacyorganizations,andcreationofpatientlocalliaisonsandadvocacytravelgrants.

42IASLC

Organizational GrowthGOAL 4 - IASLC is committed to long-term, global growth in membership.

» Meetinganaggressivegoalof5,000activemembersin2015,IASLCenrolledarecordofmorethan1,500newmembersbytheendoftheyear.

» WhilemembershiphistoricallyincreasesduringWCLCyears,IASLCimprovedthedatasharingandregistrationprocessthisyeartocapturemembershipasindividualscompletedWCLCregistration.Inaddition,manynewmemberstookadvantageofthemulti-yeardiscountofferattheWCLCinDenver.

» IASLCretainedandrecovered88percentofformermembersandlapsedmembers, whichisanincreaseoverpastyears’ retentionrates.

» IncreasedpromotionofthefreeFellowmembership,availabletoFellows,Residents,andTraineesinalldisciplines,ledtogrowthinthismembercategory.Weencourageallmembersto“Invite-a-Fellow”orutilizetheGroupFellowRegistrationtomakesureearlycareerphysiciansandinvestigatorscanbenefitfromthisincrediblevalue.

Professional Membership AssociationGOAL 5 - IASLC values the work of its volunteer members, who advance the IASLC mission through active participation and effective leadership.

» Asapilotprogram,IASLClaunchedaMembershipBoothpresenceatsocietiesforThoracicSurgery,PulmonologyandMedicalOncologyinEuropeandNorthAmerica,andwecontinuetoincreaseIASLCexposureinunder-representedspecialtiesandregionsoftheworld.

» IASLCestablishedagoalofeducatingtheentireteamofprovidersforlungcancerpatients,extendingtopathologists,diagnosticradiologists,nursesandalliedhealthprofessionals,communitypractitionersandindustryprofessionals.Tofurtherthatgoal,IASLCupdateditsmembercommunicationstoincludelanguagetomakeitclearthatIASLCmembershipisvaluabletoanyonewhoisinvolvedinlungcanceraroundtheworld.

» TheIASLCVirtualLibrarylaunchedin2015witheducationalcontentfromWCLC2015and2013availabletomembersontheIASLCwebsite.The8thEditionTNMStagingCardProposalscontinuedtobeoffered,freeofcharge,atmeetingsaroundtheworld.


Charitable Giving and Philanthropic RelationshipsGOAL 6 - IASLC solicits philanthropic funds to support its research and educational programs.

» CentraltotheIASLCandtheIASLCFoundationisthemissiontosupporttheeducationoffellowsandyounginvestigators.Since2000,theIASLChasfundedmorethan80fellowships,11inthemostrecentyear.

» ThroughgenerousgiftstotheIASLCFoundation,wecanexpandourfellowshipprogram,creatingmoreprogramsliketheInternationalMentorshipProgram.

» In2015,theFoundationhadastrongstartwithdonationslargeandsmall.WelookforwardtoexpandingdonationstotheFoundationin2016aswereachouttomembersandcommunitypartners.

Operational SoundnessGOAL 7 - To accomplish its mission, the IASLC is committed to operational excellence and fiscal responsibility.

» TheIASLCends2015withabudgetsurplusfortheyearafterresponsiblymanagingthebudget(slowlygrowingtheassetbasewhileremainingfiscallyresponsible)andafterrunningafinanciallysuccessfulWorldConference(WCLC2015).

» NegotiatingacontractwithanewpublisherfortheJTOallowstheIASLCtoleveragenewopportunities,toprovideourmemberswithinformationinnewformats,andgivestheorganizationabetterrevenuesourcefrom theJournal.

» Expansionofthe“BestOf”seriesallowsthemostrelevantandinformativescientificdatatobeaccessedbymorepeopleworldwide.

» IASLChasplanstogrowtheofficebyseveralnewmembers(newspaceisleasedandinthedesignphaseandthreeofthenewstaffmembersbeganworkinJanuary2016)inordertotakeadvantageofnewopportunitiesinthisrapidlyprogressingfield,andalsotoprovideabettervarietyofservicesforourmembers.

44IASLC

IASLC FoundationTheIASLCFoundation’smissionistosupporttheeducationoffellowsandyounginvestigatorsdestinedtobecomethenextgenerationoflungcancerphysiciansandscientists.Since2000,theIASLChasfunded 80fellowships,11inthemostrecentyear.WiththehelpoftheIASLCFoundation,wecanexpandthisnumberinthefutureandassistmorepeopleincreatingnewandbetterwaystocombatlungcancer.

Todatemembershavedonatedover$250,000tohelpfundthesefellowships.Withourexpandedfundraisingefforts,theskyisthelimit.Ifyouwouldliketodonate tothisworthycause,pleasevisitourwebsite: iaslc.org/foundation.

In2015,theFoundationhadastrongstartwithagenerousdonationfromDr.AdiF.Gazdar.RelyingonthissubstantialgiftasseedmoneyallowstheIASLCFoundationtostartfundingour2016fellowships.However,thisisjustthestart.Weanticipate2016willseegreatstridesaswegrowourdonationbase.

We are grateful for the contribution made by those on this full list of 2015 donors:

$200,000 and aboveAdiF.Gazdar

$3,000 - $5,000CarolynM.DreslerDavidR.GandaraChristianManegold

$1,000 - $3,000AlexA.Adjei

BioBridgeStrategies (in honor of Denise Aberle, MD)

PaulA.Bunn,Jr.DavidPaulCarbone

QuincyChuBenCreelan

MartinEdelmanJeffreyA.EngelmanEdwardB.GaronPeterGoldstrawDavidH.HarpoleFredR.HirschJamesR.Jett

KarenKellyAaronMansfieldJohnD.MinnaRonNatale

GregoryA.OttersonRomanPerez-Soler

NaiyerRizviLeeRosen

DavidR.SpigelRolfStahel

MasahiroTsuboiVolderWacheck

GlenandLynneWeissJamesYang

$500 - $1,000PhilipD.BonomiMichaelJ.BoyerJulieBrahmer

JeffreyCrawfordJeremyJ.ErasmusLaurieE.Gaspar

LeoraHorn

MarkG.KrisChristineLovly

JoelNealSureshS.RamalingamKarenL.ReckampCharlesM.Rudin

NicoleRuizAlanB.Sandler

SumitraThongprasertPaulVanHoutteNiseYamaguchi

Under $500ChristianAdonizioShaymaaAhmedNewtonAlvesNaokoAragane

DavidBallJamesBartlett

LyudmiaBazhenovaSusanBlackwellAliceBraae

GiovanniLCarboni

Adi F. Gazdar


LuisEduardoWerneckCarvalho

GuadalupeCedilloLeeChoon-TaekLjiljanaCilicEdwardConteJeffreyM.CraneJesusE.Davila

LarsB.DrivsholmWilfriedE.E.Eberhardt

TakashiEtoEtsuoFujita

MasahiroFukuokaAdamGamzon

ArunKumarGoelJhanelleGrayMarkR.GreenTomaszGrodzkiZhongpingGu

JamesU.GuachallaToshiyukiHarada

MasatoshiHasegawaKazushigeHayakawaNinaHelbekkmo

ThomasA.HensingFranciscoM.HeraldeIII

ShioriHikawaTeodorHorvathMichaelHumerKlausLIrion

HelgiJ.IsakssonDoloresIsla

MingLeeJangSureeratJaruhathaiTakeshiJohkoh

MichaelJonesRosalynJuergens

RyuKanzakiEdwardKimJooHangKimEbenezerKioJiroKitamuraKatsuyukiKiuraStephenC.LamCoreyJ.LangerYannLeCocguic

JayM.LeeJungShinLeeJangMingLeeNatashaLeighlRolfLewensohnTianhongLiHamadLia

KatsuakiMaeharaManuelMagallanesMitchellMageeJoAnnMoranMarceloMuinoSilviaNovelloYuichiroOheJiroOkami

MeinoshinOkumuraMariaC.PietanzaRobertPirkerIgorPolyakovZhouQingNealReady

KristinRicheimerGregoryRiely

BarbaraAnnRyan

LuciannoH.P.SantosArnoldM.Schwartz

DavidShamesKazuhikoShibataArthurTSkarinMatthewSteligaEmilyStone

ShigekiSugiyamaMinakoSumiKenjiSuzukiIrfanTastepeGuillermoJoséTemperley

MarkusTiemannMugeTor

ShinichiToyookaWilliamD.TravisMingS.Tsao

RosaireVaillancourtPaulVanSchil

GregoryM.M.VideticMaximilianvonLaffert

HeatherWakeleeWilliamWalsh

JohnWetheringtonDeborahA.WhippenStephenK.WilliamsonHiromasaYamamotoDavidF.Yankelevitz

MeiLingYapXuchaoZhangYongZhang

The legacy of

John Fisher

John Fisher became ill

in 2015 and rapidly

passed away from

mesothelioma, a thoracic

cancer. His wife, Lauren,

established a fund in

his memory, John’s

Legacy, honoring his

life’s focus on making

a difference in the lives

of others. Two-thirds

of the proceeds raised

by John’s Legacy will

go toward the IASLC

Foundation, specifically

to aid in efforts based out

of Colorado. DavidCarbone,Chair

FredR.Hirsch,CEOandSecretaryDavidGandara,TreasurerGiorgioScagliotti,Member

TonyMok,Member

IvarSamrén,MemberMarcBraunstein,Member

IASLC Foundation Board

46IASLC

TheIASLCcontinuestofocusonimplementingnewprogramsandinitiativesthathelpsupportourmembersandourmission.

Inthecomingyear,wewillgrowourmembershipandouractivities,sharingmoreknowledgeandbestpracticesaboutlungcancerthaneverbefore.In2016,theIASLCwillrenewourfocusonAsiawhilemaintainingourhighstandardsworldwide.Thisyearmarksthestartofanewage–itwillbethefirsttimetheWorldConferenceonLungCancerisheldannuallyandwelookforwardtoseeingallofourmembersinViennainDecember2016.

WhilewefocusontheimplementationoftheannualWCLC,ourcommitmentstoregionalactivitieswillcontinue.TheIASLCwillalsoexpandonregionalmeetingsinNorthAmericawithourChicagomeeting,inLatinAmericawiththeLatinAmericanLungCancerMeeting,(LALCA),inAsiawiththeAsianPacificLungCancerMeeting

(APLCC),andtogetherwithESMOinEurope,theEuropeanLungCancerMeeting(ELCC).

TheIASLCalsoacknowledgestheimportanceofhavingexpertsfocusingonspecifictopicsandprovidingguidanceforfuturedevelopmentsinspecificareas,andtherefore,wewillexpandourmeetingportfoliotoincludesmaller-focusedmeetings.Wewillalsofocusonprovidingguidancethroughscientificprojects,suchasthenewPD-L1Blueprint,andpublicationssuchastherevisedALK-ROS1Atlas.

Ourmembershipcontinuestoexpand,includingadvocates,patients,nursesandfieldrepresentatives.Wenowhavemembersinnearly100differentcountriesasmorepeopleinourfieldrecognizeIASLCasthegloballeaderinlungcancer.

TheIASLCFoundationgarnersmoresupportweeklyaswecontinuetouncoveroutreachopportunitiesparticularlyinsupportofmorefellowshipsandeducationalactivities.Inaddition,asdemandgrowsforthesupportfromtheIASLCstaff,wewillexpandboththenumberofourstaffandthesizeoftheheadquartersspace.

Inthecomingyear,wewillcontinuetoupdatetheIASLC/CAP/AMPguidelinesformoleculartestingforpersonalizedtherapy.TheIASLC,inconjunctionwithUICC,willpublishthenew(8thedition)stagingsystemforintrathoracictumorsbasedon

workbytheIASLCPathologyCommittee.ThecommitteewillalsowidelydistributethenewWHO Classification of Tumours of the Lung, Pleura, Thymus and Heart.

In2016,theIASLChopestoestablishaworldwidemoleculardatabasetoprovideinvestigatorswithopportunitiestocorrelatenumerousmolecularabnormalities,manyofwhicharerare,toclinical,demographicandtreatmentcharacteristics.Additionally,lookforthearrivalofotherIASLCprogramsthatwillaidincommunicationbetweenhealthprofessionalsandpatientsandexpandourreach.

TheIASLCwillalsocontinuetohostmeetingsacrosstheglobe,largeandsmall,beforeweculminatewiththeWCLCinDecember.Itisthroughtheseopportunitiestoshareknowledgewitheachotherthatwecan movethelineinthefightagainst lungcancer.

Weknowthatlungcancerscreeningcanreducelungcancermortalitysignificantlyandisrecommendedforthosedefinedashigh-risk.TheIASLCwillcontinuetoencouragemorescreeningaroundtheworld.Wearealsolookingtothefuturefornewandbetterwaystodetectthoracicmalignanciesearlier,aswellasfocusingontobaccocontrolandbetterpreventionmeasures,aswecontinueourmissiontoreducelungcancermortalityallovertheworld.

Future Perspective


IASLC in PublicationsAstheonlyglobalmedicalsocietydedicatedtoconqueringthoracicmalignances,IASLC’sactivities,especiallytheWCLC,servedasthebasisformanypublicationsandresearchstudiesin2015.ThefollowinglistcontainscitationsofthosepublicationsaslistedinPubMed,forthecriteria“IASLC”or“InternationalAssociationfortheStudyofLungCancer.”IASLC’sreputationandrecognitioncontinuestogrowasmembersandnon-membersreferencetheorganizationintheirwork.

Aproteomicprofilingoflaser-microdissectedlungadenocarcinomacellsofearlylepidic-types.

KatoY,NakamuraH,TojoH,NomuraM,NagaoT,KawamuraT,KodamaT,OhiraT,IkedaN,FehnigerT,Marko-VargaG,NishimuraT,KatoH.

ClinTranslMed.2015Dec;4(1):64.doi:10.1186/s40169-015-0064-3.Epub2015Jul3.

AccuracyoftheIASLC/ATS/ERShistologicalsubtypingofstageIlungadenocarcinomaonintraoperativefrozensections.

TrejoBittarHE,IncharoenP,AlthouseAD,DacicS.

ModPathol.2015Aug;28(8):1058-63.doi:10.1038/modpathol.2015.71.Epub2015May29.

Associationbetweenhigh-resolutioncomputedtomographyfindingsandtheIASLC/ATS/ERSclassificationofsmalllungadenocarcinomasinJapanesepatients.

KudoY,MatsubayashiJ,SajiH,AkataS,ShimadaY,KatoY,KakihanaM,KajiwaraN,OhiraT,NagaoT,IkedaN.

LungCancer.2015Oct;90(1):47-54.doi:10.1016/j.lungcan.2015.07.007.Epub2015Jul26.

AssociationofIASLC/ATS/ERSHistologicSubtypesofLungAdenocarcinomaWithEpidermalGrowthFactorReceptorMutationsin320ResectedCases.

NakamuraH,SajiH,ShinmyoT,TagayaR,KurimotoN,KoizumiH,TakagiM.

ClinLungCancer.2015May;16(3):209-15.doi:10.1016/j.cllc.2014.10.004.Epub2014Oct25.

Changeofjunctionsbetweenstations10and4inthenewInternationalAssociationfortheStudyofLungCancerLymphNodeMap:avalidationstudyfromasingle,tertiaryreferralhospitalexperience.

LeeS,LeeHY,LeeKS,YieM,ZoJ,ShimYM,HanJ,AhnJH.

Chest.2015May;147(5):1299-306.doi:10.1378/chest.14-0717.

Clinicalevaluationofanewtumour-node-metastasisstagingsystemforthymicmalignanciesproposedbytheInternationalAssociationfortheStudyofLungCancerStagingandPrognosticFactorsCommitteeandtheInternationalThymicMalignancyInterestGroup.

FukuiT,FukumotoK,OkasakaT,KawaguchiK,NakamuraS,HakiriS,OzekiN,HirakawaA,TateyamaH,YokoiK.

EurJCardiothoracSurg.2015Nov7.doi:pii:ezv389.[Epubaheadofprint]

ClinicalimpactofthenewIASLC/ATS/ERSlungadenocarcinomaclassificationforchestsurgeons.

NakamuraH,TakagiM. SurgToday.2015Nov;45(11):1341-51.doi:10.1007/s00595-014-1089-8.Epub2014Nov23.

CloseassociationofIASLC/ATS/ERSlungadenocarcinomasubtypeswithglucose-uptakeinpositronemissiontomography.

NakamuraH,SajiH,ShinmyoT,TagayaR,KurimotoN,KoizumiH,TakagiM.

LungCancer.2015Jan;87(1):28-33.doi:10.1016/j.lungcan.2014.11.010.Epub2014Nov27.

Closerelationoflargecellcarcinomatoadenocarcinomabyhierarchicalclusteranalysis:implicationsforhistologictypingoflungcanceronbiopsies.

HammerSH,PrallF. ApplImmunohistochemMolMorphol.2015Sep;23(8):550-7.doi:10.1097/PAI.0000000000000121.

CorrelationbetweenMETproteinexpressionandMETgenecopynumberinaCaucasiancohortofnon-smallcelllungcancersaccordingtothenewIASLC/ATS/ERSclassification.

WeingertnerN,MeyerN,VoegeliAC,GuenotD,RenaudS,MassardG,FalcozPE,OllandA,MennecierB,GaubMP,LindnerV,GhnassiaJP,QuoixE,ChenardMP,Beau-FallerM.

Pathology.2015Jun;47(4):320-8.doi:10.1097/PAT.0000000000000269.

48IASLC

Correlationsbetweenpathologicsubtypes/immunohistochemicalimplicationandCTcharacteristicsoflungadenocarcinomaâ‰¤1cmwithground-glassopacity.

WuF,CaiZL,TianSP,JinX,JingR,YangYQ,LiYN,ZhaoSH.

ZhongguoYiXueKeXueYuanXueBao.2015Apr;37(2):163-70.doi:10.3881/j.issn.1000-503X.2015.02.006.

CytopathologyofpulmonaryadenocarcinomawithasinglehistologicalpatternusingtheproposedInternationalAssociationfortheStudyofLungCancer/AmericanThoracicSociety/EuropeanRespiratorySociety(IASLC/ATS/ERS)classification.

RodriguezEF,DacicS,PantanowitzL,KhalbussWE,MonacoSE.

CancerCytopathol.2015May;123(5):306-17.doi:10.1002/cncy.21532.Epub2015Mar18.

Developmentandvalidationofanomogramforpredictingsurvivalinpatientswithresectednon-small-celllungcancer.

LiangW,ZhangL,JiangG,WangQ,LiuL,LiuD,WangZ,ZhuZ,DengQ,XiongX,ShaoW,ShiX,HeJ.

JClinOncol.2015Mar10;33(8):861-9.doi:10.1200/JCO.2014.56.6661.Epub2015Jan26.

Diagnosticyieldofendobronchialultrasound-guidedtransbronchialneedleaspirationformediastinalstaginginlungcancer.

Fernández-BussyS,LabarcaG,CanalsS,CaviedesI,FolchE,MajidA.

JBrasPneumol.2015May-Jun;41(3):219-24.doi:10.1590/S1806-37132015000004466.English,Spanish.

EGFRanalysis:currentevidenceandfuturedirections.

BellevicineC,MalapelleU,deLucaC,IaccarinoA,TronconeG.

DiagnCytopathol.2014Nov;42(11):984-92.doi:10.1002/dc.23142.Epub2014Mar12.Review.

EGFRL858Rmutationisassociatedwithlungadenocarcinomapatientswithdominantground-glassopacity.

YangY,YangY,ZhouX,SongX,LiuM,HeW,WangH,WuC,FeiK,JiangG.

LungCancer.2015Mar;87(3):272-7.doi:10.1016/j.lungcan.2014.12.016.Epub2015Jan5.

EvaluationoftheproposedInternationalAssociationfortheStudyofLungCancer(IASLC)/InternationalThymicMalignanciesInterestGroup(ITMIG)stagingrevisionsinthymicwell-differentiatedneuroendocrinecarcinomapatients.

ZhaoY,ShiJ,FanL,YangJ,HuD,ZhaoH. EurJCardiothoracSurg.2015May1.doi:pii:ezv137.[Epubaheadofprint]

Follow-upofpatientsafterstereotacticradiationforlungcancer:aprimerforthenonradiationoncologist.

HuangK,PalmaDA;IASLCAdvancedRadiationTechnologyCommittee.

JThoracOncol.2015Mar;10(3):412-9.doi:10.1097/JTO.0000000000000435.

IdentifyingTargetedStrategiestoImproveSmokingCessationSupportforCancerPatients.

WarrenGW,DibajS,HutsonA,CummingsKM,DreslerC,MarshallJR.

JThoracOncol.2015Nov;10(11):1532-7.doi:10.1097/JTO.0000000000000659.

ImpactoftheInternationalAssociationfortheStudyofLungCancer/AmericanThoracicSociety/EuropeanRespiratorySocietyclassificationofstageIAadenocarcinomaofthelung:CorrelationbetweencomputedtomographyimagesandEGFRandKRASgenemutations.

WangT,ZhangT,HanX,LiuXI,ZhouN,LiuY. ExpTherMed.2015Jun;9(6):2095-2103.Epub2015Apr14.

InternationalAssociationfortheStudyofLungCancer/AmericanThoracicSociety/EuropeanRespiratorySocietyclassificationpredictsoccultlymphnodemetastasisinclinicallymediastinalnode-negativelungadenocarcinoma.

YehYC,KadotaK,NitadoriJI,SimaCS,RizkNP,JonesDR,TravisWD,AdusumilliPS.

EurJCardiothoracSurg.2015Sep15.doi:pii:ezv316.[Epubaheadofprint]

Lungadenocarcinoma:SustainedsubtypingwithimmunohistochemistryandEGFR,HER2andKRASmutationalstatus.

SousaV,RodriguesC,SilvaM,AlarcãoAM,CarvalhoL.

RevPortPneumol(2006).2015May-Jun;21(3):113-25.doi:10.1016/j.rppnen.2014.09.009.Epub2015Mar11.

Lungcancerandconcurrentorsequentiallymphoma:Twocasereportswithhypersensitivitytobevacizumabandareviewoftheliterature.

PezzutoA,PirainoA,MariottaS. OncolLett.2015Feb;9(2):604-608.Epub2014Nov20.


Metastaticindexofnon-small-celllungcancerandlong-termsurvival.

PoullisM,ShackclothM,PageR,Asanti-SiawJ,WoolleyS,MedirattaN.

AsianCardiovascThoracAnn.2015Feb;23(2):185-90.doi:10.1177/0218492314545833.Epub2014Aug7.

MitosistrumpsTstageandproposedinternationalassociationforthestudyoflungcancer/americanthoracicsociety/europeanrespiratorysocietyclassificationforprognosticvalueinresectedstage1lungadenocarcinoma.

DuhigEE,DettrickA,GodboltDB,PauliJ,vanZwietenA,HansenAR,YangIA,FongKM,ClarkeBE,BowmanRV.

JThoracOncol.2015Apr;10(4):673-81.doi:10.1097/JTO.0000000000000446.

Mitoticarrestdeficient-like1iscorrelatedwithpoorprognosisinsmall-celllungcanceraftersurgicalresection.

LiD,MengQ,ZhangH,FengT,LiuM,CaiL. TumourBiol.2015Oct24.[Epubaheadofprint]

Molecularalterationsinnon-small-celllungcancer:perspectivefortargetedtherapyandspecimenmanagementforthebronchoscopist.

Czarnecka-KujawaK,YasufukuK. Respirology.2014Nov;19(8):1117-25.doi:10.1111/resp.12377.

Moleculartestingforselectionofpatientswithlungcancerforepidermalgrowthfactorreceptorandanaplasticlymphomakinasetyrosinekinaseinhibitors:americansocietyofclinicaloncologyendorsementofthecollegeofamericanpathologists/internationalassociationforthestudyoflungcancer/associationformolecularpathologyguideline.

RekhtmanN,LeighlNB,SomerfieldMR. JOncolPract.2015Mar;11(2):135-6.doi:10.1200/JOP.2014.002303.Epub2014Dec16.Noabstractavailable.

Multimodalitytherapyforlocallyadvancedthymomas:Apropensityscore-matchedcohortstudyfromtheEuropeanSocietyofThoracicSurgeonsDatabase.

LeuzziG,RoccoG,RuffiniE,SperdutiI,DetterbeckF,WederW,VenutaF,VanRaemdonckD,ThomasP,FaccioloF;ESTSThymicWorkingGroup.

JThoracCardiovascSurg.2015Aug15.doi:pii:S0022-5223(15)01481-6.10.1016/j.jtcvs.2015.08.034.[Epubaheadofprint]

MutationalProfileandNewIASLC/ATS/ERSClassificationProvideAdditionalPrognosticInformationaboutLungAdenocarcinoma:AStudyof125PatientsfromBrazil.

deMeloAC,KarendeSáV,SternbergC,OlivieriER,WerneckdaCunhaI,FabroAT,CarraroDM,deBarroseSilvaMJ,PimentaInadaHK,deMelloES,SoaresFA,TakagakiT,FerreiraCG,CapelozziVL.

Oncology.2015;89(3):175-86.doi:10.1159/000376552.Epub2015Apr1.

Nonpredominantlepidicpatterncorrelateswithbetteroutcomeininvasivelungadenocarcinoma.

MäkinenJM,LaitakariK,JohnsonS,MäkitaroR,BloiguR,Lappi-BlancoE,KaarteenahoR.

LungCancer.2015Oct17.doi:pii:S0169-5002(15)30083-0.10.1016/j.lungcan.2015.10.014.[Epubaheadofprint]

Nuclearestrogenreceptor-αexpressionisanindependentpredictorofrecurrenceinmalepatientswithpT1aN0lungadenocarcinomas,andcorrelateswithregulatoryT-cellinfiltration.

KadotaK,EguchiT,Villena-VargasJ,WooKM,SimaCS,JonesDR,TravisWD,AdusumilliPS.

Oncotarget.2015Sep29;6(29):27505-18.doi:10.18632/oncotarget.4752.

OutsourcingcytologicalsamplestoareferrallaboratoryforEGFRtestinginnon-smallcelllungcancer:doestheorymeetpractice?

VigliarE,MalapelleU,BellevicineC,deLucaC,TronconeG.

Cytopathology.2015Oct;26(5):312-7.doi:10.1111/cyt.12221.Epub2014Nov7.

PeripherallungadenocarcinomaswithKRASmutationsaremorelikelytoinvadevisceralpleura.

RapariaK,VillaC,RajR,CaglePT. ArchPatholLabMed.2015Feb;139(2):189-93.doi:10.5858/arpa.2013-0759-OA.Epub2014Apr2.

Perspectivesofnovelimagingtechniquesforstaging,therapyresponseassessment,andmonitoringofsurveillanceinlungcancer:summaryoftheDresden2013PostWCLC-IASLCState-of-the-ArtImagingWorkshop.

HenzlerT,GoldstrawP,WenzF,PirkerR,WederW,ApfaltrerP,MeyerM,BuesingK,CrinoL,FennellD,FinkC,GrunenwaldD,ManegoldC,PilzL,SchoenbergSO,SureshS,VansteenkisteJ,VoigtW,WänglerB,Schmid-BindertG.

JThoracOncol.2015Feb;10(2):237-49.doi:10.1097/JTO.0000000000000412.

50IASLC

Predictingtheprognosisoflungcancer:theevolutionoftumor,nodeandmetastasisinthemolecularage-challengesandopportunities.

Rami-PortaR,AsamuraH,GoldstrawP. TranslLungCancerRes.2015Aug;4(4):415-23.doi:10.3978/j.issn.2218-6751.2015.07.11.

Prognosticimpactandclinicopathologicalcorrelationsofthecribriformpatterninpulmonaryadenocarcinoma.

WarthA,MuleyT,KossakowskiC,StenzingerA,SchirmacherP,DienemannH,WeichertW.


Prognosticimpactofpattern-basedgradingsystembythenewIASLC/ATS/ERSclassificationinAsianpatientswithstageIlungadenocarcinoma.

ZhaoZR,XiSY,LiW,SituDR,ChenKM,YangH,SuXD,LinYB,LongH.

LungCancer.2015Nov4.doi:pii:S0169-5002(15)30095-7.10.1016/j.lungcan.2015.10.026.[Epubaheadofprint]

PrognosticvalueoftheIASLC/ATS/ERSclassificationandIMP3expressioninlungadenocarcinomaofChinesecases.

SunX,WeiP,ShenC,YangY,WangY,LiY,DuX.

AmJCancerRes.2015;5(7):2266-76.

PrognosticvalueofthenewIASLC/ATS/ERSclassificationofclinicalstageIAlungadenocarcinoma.

MurakamiS,ItoH,TsubokawaN,MimaeT,SasadaS,YoshiyaT,MiyataY,YokoseT,OkadaM,NakayamaH.

LungCancer.2015Nov;90(2):199-204.doi:10.1016/j.lungcan.2015.06.022.Epub2015Jul2.

PrognosticvalueofthenewInternationalAssociationfortheStudyofLungCancer/AmericanThoracicSociety/EuropeanRespiratorySocietyclassificationinstageIBlungadenocarcinoma.

XuCH,WangW,WeiY,HuHD,ZouJ,YanJ,YuLK,YangRS,WangY.

EurJSurgOncol.2015Oct;41(10):1430-6.doi:10.1016/j.ejso.2015.06.004.Epub2015Jun23.

ProgrammedDeath-Ligand1ImmunohistochemistryinLungCancer:Inwhatstateisthisart?

KerrKM,TsaoMS,NicholsonAG,YatabeY,WistubaII,HirschFR;IASLCPathologyCommittee.

JThoracOncol.2015Jul;10(7):985-9.doi:10.1097/JTO.0000000000000526.

RadiologicEvaluationofSmallLepidicAdenocarcinomastoGuideDecisionMakinginSurgicalResection.

WilshireCL,LouieBE,ManningKA,HortonMP,CastiglioniM,GordenJA,AyeRW,FarivarAS,VallièresE.

AnnThoracSurg.2015Sep;100(3):979-88.doi:10.1016/j.athoracsur.2015.04.030.Epub2015Jul29.

RadiologicPredictorsforClinicalStageIALungAdenocarcinomawithGroundGlassComponents:AMulti-CenterStudyofLong-TermOutcomes.

LiZ,YeB,BaoM,XuB,ChenQ,LiuS,HanY,PengM,LinZ,LiJ,ZhuW,LinQ,XiongL.

PLoSOne.2015;10(9):e0136616.doi:10.1371/journal.pone.0136616.

Relationshipbetweenhistopathologiccharacteristicsandepidermalgrowthfactorreceptormutationinlungadenocarcinoma.

WangK,GongH,LiX,YangZ,CaoP,WandC,JiangY,WangH,WangY,ZhangG.

ZhonghuaBingLiXueZaZhi.2015Mar;44(3):170-4.Chinese.

Reproducibilityof3histologicclassificationsand3stagingsystemsforthymicepithelialneoplasmsanditseffectonprognosis.

RodenAC,YiES,JenkinsSM,EdwardsKK,DonovanJL,LewisJE,CassiviSD,MarksRS,GarcesYI,AubryMC.

AmJSurgPathol.2015Apr;39(4):427-41.doi:10.1097/PAS.0000000000000391.

RoleofCTandPETImaginginPredictingTumorRecurrenceandSurvivalinPatientswithLungAdenocarcinoma:AComparisonwiththeInternationalAssociationfortheStudyofLungCancer/AmericanThoracicSociety/EuropeanRespiratorySocietyClassificationofLungAdenocarcinoma.

LeeHY,LeeSW,LeeKS,JeongJY,ChoiJY,KwonOJ,SongSH,KimEY,KimJ,ShimYM.

JThoracOncol.2015Oct15.[Epubaheadofprint]

SolidcomponentandtumorsizecorrelatewithprognosisofstageIBlungadenocarcinoma.

XuS,XiJ,JiangW,LuS,WangQ. AnnThoracSurg.2015Mar;99(3):961-7.doi:10.1016/j.athoracsur.2014.10.079.Epub2015Jan27.

SolidPredominantHistologicSubtypeinResectedStageILungAdenocarcinomaIsanIndependentPredictorofEarly,Extrathoracic,MultisiteRecurrenceandofPoorPostrecurrenceSurvival.

UjiieH,KadotaK,ChaftJE,BuitragoD,SimaCS,LeeMC,HuangJ,TravisWD,RizkNP,RudinCM,JonesDR,AdusumilliPS.

JClinOncol.2015Sep10;33(26):2877-84.doi:10.1200/JCO.2015.60.9818.Epub2015Aug10.


Stereotacticablativeradiotherapyforcentrallylocatedearlystagenon-small-celllungcancer:whatwehavelearned.

ChangJY,BezjakA,MornexF;IASLCAdvancedRadiationTechnologyCommittee.


Subsolidpulmonarynodules:CT-pathologiccorrelationusingthe2011IASLC/ATS/ERSclassification.

LiaoJH,AminVB,KadochMA,BeasleyMB,JacobiAH.

ClinImaging.2015May-Jun;39(3):344-51.doi:10.1016/j.clinimag.2014.12.009.Epub2014Dec20.Review.

SubtypeClassificationofLungAdenocarcinomaPredictsBenefitFromAdjuvantChemotherapyinPatientsUndergoingCompleteResection.

TsaoMS,MarguetS,LeTeuffG,LantuejoulS,ShepherdFA,SeymourL,KratzkeR,GrazianoSL,PopperHH,RosellR,DouillardJY,Le-ChevalierT,PignonJP,SoriaJC,BrambillaEM.

JClinOncol.2015Oct20;33(30):3439-46.doi:10.1200/JCO.2014.58.8335.Epub2015Apr27.

Theanaplasticlymphomakinasetestingconundrum.

CondeE,TaniereP,Lopez-RiosF. ExpertRevMolDiagn.2015Feb;15(2):161-3.doi:10.1586/14737159.2015.997713.Epub2015Jan12.

TheclinicalutilityofMemorialSymptomAssessment-ShortFormandCondensedMemorialSymptomAssessmentScaleinTurkishlungcancerpatients.

YüceegeM,SanisoğluB,FıratH,ErsoyY,SevgiE,KurtEB.

ClinRespirJ.2015Apr;9(2):221-7.doi:10.1111/crj.12127.Epub2014Mar20.

TheIASLCLungCancerStagingProject:ProposalsfortheRevisionoftheMDescriptorsintheForthcomingEighthEditionoftheTNMClassificationofLungCancer.

EberhardtWE,MitchellA,CrowleyJ,KondoH,KimYT,TurrisiA3rd,GoldstrawP,Rami-PortaR;InternationalAssociationfortheStudyofLungCancerStagingandPrognosticFactorsCommittee,AdvisoryBoardMembers,andParticipatingInstitutions.

JThoracOncol.2015Nov;10(11):1515-22.doi:10.1097/JTO.0000000000000673.

TheIASLCLungCancerStagingProject:ProposalsfortheRevisionsoftheTDescriptorsintheForthcomingEighthEditionoftheTNMClassificationforLungCancer.

Rami-PortaR,BolejackV,CrowleyJ,BallD,KimJ,LyonsG,RiceT,SuzukiK,ThomasCFJr,TravisWD,WuYL;IASLCStagingandPrognosticFactorsCommittee,AdvisoryBoardsandParticipatingInstitutions.

JThoracOncol.2015Jul;10(7):990-1003.doi:10.1097/JTO.0000000000000559.

TheInternationalAssociationfortheStudyofLungCancerLymphNodeMap:ARadiologicAtlasandReview.

KimJH,vanBeekEJ,MurchisonJT,MarinA,MirsadraeeS.

TubercRespirDis(Seoul).2015Jul;78(3):180-9.doi:10.4046/trd.2015.78.3.180.Epub2015Jun30.Review.

TheInternationalThymicMalignancyInterestGroupthymicinitiative:astate-of-the-artstudyofthymicmalignancies.

DetterbeckF,KorstR. SeminThoracCardiovascSurg.2014Winter;26(4):317-22.doi:10.1053/j.semtcvs.2015.02.002.Epub2015Feb7.

TreatmentofPeripheralNon-SmallCellLungCarcinomawithStereotacticBodyRadiationTherapy.

RoachMC,VideticGM,BradleyJD;IASLCAdvancedRadiationTechnologyCommittee.

JThoracOncol.2015Sep;10(9):1261-7.doi:10.1097/JTO.0000000000000610.

TumoralCD10expressioncorrelateswithhigh-gradehistologyandincreasesriskofrecurrenceinpatientswithstageIlungadenocarcinoma.

KadotaK,BuitragoD,LeeMC,Villena-VargasJ,SimaCS,JonesDR,TravisWD,AdusumilliPS.

LungCancer.2015Sep;89(3):329-36.doi:10.1016/j.lungcan.2015.06.003.Epub2015Jun15.

UsingfrozensectiontoidentifyhistologicalpatternsinstageIlungadenocarcinomaof≤3cm:accuracyandinterobserveragreement.

YehYC,NitadoriJ,KadotaK,YoshizawaA,RekhtmanN,MoreiraAL,SimaCS,RuschVW,AdusumilliPS,TravisWD.

Histopathology.2015Jun;66(7):922-38.doi:10.1111/his.12468.Epub2015Feb5.

UtilizationoftheInternationalAssociationfortheStudyofLungCancerandWang’snodalmapfortheidentificationofmediastinumandhilarlymphnodes.

XiaY,MaY,AriasS,LeeH,WangKP. ThoracCancer.2015Jul;6(4):464-8.doi:10.1111/1759-7714.12206.Epub2015Jan8.

Video-assistedthoracoscopicsurgerylobectomyforlungcancerisassociatedwithalower30-daymorbiditycomparedwithlobectomybythoracotomy.

LaursenLØ,PetersenRH,HansenHJ,JensenTK,RavnJ,KongeL.

EurJCardiothoracSurg.2015Jun18.doi:pii:ezv205.[Epubaheadofprint]

52IASLC

13100 East Colfax Avenue, Unit 10 | Auora, Colorado, USA 80011 | www.iaslc.org

iaslc 2015 annual report

Documents